Regulation of intestinal cholesterol transport and metabolism by high glucose levels = Régulation intestinale du transport et du métabolisme du cholestérol par le glucose by Ravid Leibovici, Rosa Zaava
 
Direction des bibliothèques 
 
 
 
AVIS 
 
Ce document a été numérisé par la Division de la gestion des documents et 
des archives de l’Université de Montréal. 
 
L’auteur a autorisé l’Université de Montréal à reproduire et diffuser, en totalité 
ou en partie, par quelque moyen que ce soit et sur quelque support que ce 
soit, et exclusivement à des fins non lucratives d’enseignement et de 
recherche, des copies de ce mémoire ou de cette thèse.  
 
L’auteur et les coauteurs le cas échéant conservent la propriété du droit 
d’auteur et des droits moraux qui protègent ce document. Ni la thèse ou le 
mémoire, ni des extraits substantiels de ce document, ne doivent être 
imprimés ou autrement reproduits sans l’autorisation de l’auteur.  
 
Afin de se conformer à la Loi canadienne sur la protection des 
renseignements personnels, quelques formulaires secondaires, coordonnées 
ou signatures intégrées au texte ont pu être enlevés de ce document. Bien 
que cela ait pu affecter la pagination, il n’y a aucun contenu manquant. 
 
NOTICE 
 
This document was digitized by the Records Management & Archives 
Division of Université de Montréal. 
 
The author of this thesis or dissertation has granted a nonexclusive license 
allowing Université de Montréal to reproduce and publish the document, in 
part or in whole, and in any format, solely for noncommercial educational and 
research purposes. 
 
The author and co-authors if applicable retain copyright ownership and moral 
rights in this document. Neither the whole thesis or dissertation, nor 
substantial extracts from it, may be printed or otherwise reproduced without 
the author’s permission. 
 
In compliance with the Canadian Privacy Act some supporting forms, contact 
information or signatures may have been removed from the document. While 
this may affect the document page count, it does not represent any loss of 
content from the document.  
 
 
 
Université de Montréal 
REGULATION OF INTESTINAL CHOLESTEROL TRANSPORT AND 
METABOLISM BY HIGH GLUCOSE LEVELS 
RÉGULATION INTESTINALE DU TRANSPORT ET DU MÉTABOLISME 
DU CHOLESTÉROL PAR LE GLUCOSE 
par 
Rosa Zaava Ravid Leibovici 
Département de pathologie et biologie cellulaire 
Faculté de Médecine 
Mémoire présenté à la Faculté des études supérieures 
en vue de l'obtention du grade de Maître ès sciences (M.Sc.) 
en biologie cellulaire 
Août, 2008 
©ROSA ZAA V A RA VrD LEIBOVrCr, 20 
Identification du jury 
Université de Montréal 
Faculté des études supérieures 
Ce mémoire intitulé: 
REGULATION OF. INTESTINAL CHOLESTEROL TRANSPORT AND 
METABOLISM BY HIGH GLUCOSE LEVELS 
présenté par: 
Rosa Zaava Ravid Leibovici 
a été évalué par un jury composé des personnes suivantes : 
Dr. Lucian Ghitescu 
président-rapporteur 
Dr. Moïse Bendayan 
directeur de recherche 
Dr. Emile Levy 
codirecteur 
Dr. Edgard Delvin 
membre du jury 
Il 
111 
Abstract 
Growing evidence suggests that the small intestine may contribute to excessive 
postprandial lipemia, which is highly prevalent in insulin-resistantltype 2 diabetic 
individuals increasing the risk of cardiovascular disease. The aim of the present 
study was to determine the role of high glucose levels on intestinal cholesterol 
absorption, cholesterol transporter expression, enzymes controlling cholesterol 
homeostasis and the status of transcription factors. To this end, we employed highly 
differentiated and polarized intestinal cells, Caco-2 cells, plated on permeable 
polycarbonate filters. Four major technical approaches were used, 
immunocytochemistry in electron microscopy, western blot, RT-PCR and the 
assessment of enzymatic activities. The levels of cellular cholesterol uptake were 
measured by radio-Iabeling. 
In the presence of radiolabeled cholesterol, glucose at 25 mM stimulated its uptake 
as compared to 5 mM glucose. The high concentration of glucose enhanced the 
protein expression of the critical cholesterol transporters NPCILI and CD36 and 
concomitantly decreased SR-BI protein expression. No significant changes were 
observed for ABCAI and ABCG8, which act as efflux pumps favoring cholesterol 
export out of absorptive cells. At the same time, HMG-CoA reductase activity was 
significantly decreased, whereas ACAT activity remained unchanged. Finally, 
increments were noted in the transcription factors LXRa, LXRP, pp ARp and 
PPARy along with a drop in the protein expression of SREBP-2. 
Collectively, our data indicate that glucose at high concentrations may regulate 
intestinal cholesterol transport and metabolism, thus suggesting a potential influence 
on the cholesterol absorption process in type 2 diabetes. 
Key words: ABCAI, ABCG5/G8, SR-BI, CD36, NPCILl, PPAR, LXR, SREBP, 
ACAT and HMG-CoA reductase 
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Résumé 
Plusieurs évidences suggèrent que l'intestin contribue à l'hyperlipidémie 
postprandiale fortement répandue chez les individus souffrant de résistance à 
insuline et de diabète de type-2, augmentant ainsi les risques de développer des 
maladies cardio-vasculaires. Le but de notre étude fut de déterminer, au niveau 
intestinal, le rôle du glucose dans l'absorption du cholestérol, l'expression des 
transporteurs du cholestérol et celle des enzymes qui régulent l'homéostasie du 
cholestérol et le statut des facteurs de transcription. À cet effet, nous avons 
ensemencé des cellules intestinales différenciées et polarisées, des cellules Caco-2, 
sur des filtres en polycarbonate perméables. Quatre grandes approches techniques 
ont été utilisées, l'immuno-cytochimie en microscopie électronique, 
l'immunobuvardage, le RT-PCR, et la mesure des activités enzymatiques. Les 
niveaux d'absorption du cholestérol cellulaire ont été mesurés par radio marquage. 
En présence de cholestérol radio marqué, le glucose à 25 mM stimule l'absorption 
du cholestérol comparativement aux cellules supplémentées avec 5 mM de glucose. 
La concentration élevée de glucose accroît l'expression protéique des transporteurs 
NPCILI et CD36 et diminue l'expression de la protéine SR-BI. On n'a observé 
aucun changement significatif dans l'expression des protéines ABCAI et ABCG8, 
pompes d'efflux favorisant l'exportation du cholestérol hors des cellules intestinales. 
L'activité de l'enzyme HMG-CoA réductase diminue tandis que celle de l'ACAT 
demeure inchangée. Finalement, une augmentation des facteurs de transcription 
LXRa, LXR~, PP AR~ et PPARy et une baisse de l'expression protéique de SREBP-
2 ont été observées à fortes concentrations de glucose. 
En conclusion, nos données indiquent que le glucose à des concentrations élevées, 
peut moduler le transport et le métabolisme intestinal du cholestérol suggérant une 
influence potentielle sur le processus d'absorption du cholestérol dans le diabète de 
type 2. 
Mots clés: ABCAI, ABCG5/G8, SR-BI, CD36, NPCILI, PPAR, LXR, SREBP, 
ACAT and HMG-CoA réductase 
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Introduction 
Cholesterol is an essential component of cellular membranes, a precursor of steroid 
hormones, vitamin D and bile acids, and plays a crucial role in transcriptional gene 
regulation. Excessive cholesterol, however, is cytotoxic and may cause 
atherosclerotic lesions. Therefore, a balance must be maintained between 
cholesterol intake, absorption/excretion and synthesis. For its transport within the 
enterocytes, cholesterol requires a protein-dependent machinery, including SR-BI, 
NPCILI and CD36, involved in mediating intestinal cholesterol uptake. Other 
proteins such as ABCAI and ABCG5/ABCG8 favor the exit of cholesterol from the 
enterocytes into the intestinal lumen or through the basolateral membrane. Several 
of these cholesterol carriers influence intracellular cholesterol homeostasis and are 
controlled by transcription factors, including RXR, LXR, SREBP-2 and PPAR. 
Previous studies showed that lipid components exert a regulatory effect on intestinal 
fat uptake. However, the role 'of carbohydrates has barely been investigated. 
Therefore, we aimed to evaluate the effect of glucose on cholesterol transport and 
metabolism. Establishing this relation may contribute to find new alternative 
therapeutic treatments, which improve the conditions of metabolic glucose- and 
lipid-related diseases such as obesity, coronary heart disease and diabetes mellitus 
among others. 
In the present study, we show in an in vitro model closely resembling in situ 
intestinal cells that high glucose concentrations enhance cholesterol transport by 
upregulating the prote in expression ofNPCILI and CD36. In addition, we found a 
reduced SR-BI prote in expression and HMG-CoA reductase activity, a key enzyme 
in the cholesterol biosynthesis pathway, without altering the proteins ABCAI and 
ABCG8. Moreover, our studies document that the expression of particular 
transcription factors are regulated by glucose levels. Our data indicate that glucose 
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at high concentrations may regulate intestinal cholesterol transport and metabolism, 
thus suggesting a potential influence on the cholesterol absorption process in type 2 
diabetes. 
3 
1. Cholesterol 
Cholesterol belongs to the sterol family and is present in the membranes of most 
eukaryotic cells. The characteristic structure of those lipids is the steroid nucleus, 
consisting of fused rings, three with six carbons and one with five. Sterols fulfill 
several indispensable roles in all eukaryotic cells. In mammals, cholesterol is the 
most important one. It is amphipathic with a polar head group and a nonpolar 
hydrocarbon body (Figure l). Its hydrophobicity is responsible for the valuable 
property necessary to control cell membrane fluidity (Ohvo-Rekila et al., 2002). 
However, it makes it very difficult to handle in the aqueous environment of the 
body, both within and between cells. Therefore, sophisticated mechanisms exist to 
transport cholesterol to its numerous cellular destinations. 
Polar 
head 
Fig~re 1. Cholesterol structure 
Alkyl side 
chain 
Sterol 
nucleus 
Cholesterol is an integral part of cells as well as organelle membranes and is a 
precursor of important physiological molecules, like bile salts and steroid hormones 
and is thus essential for normal cell functioning (Maxfield and Tabas, 2005). 
Defects in cholesterol synthesis or transport can have harmful consequences. 
Furthermore, cholesterol and sterols that are ubiquitously present in the diet also 
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pose a potential danger. They are critically involved III the development of 
atherosclerosis. Rence, cellular cholesterol homeostasis and plasma cholesterol 
levels have to be strictly regulated. 
Cholesterol enters the lumen of the small intestine from 3 sources: diet, bile, and 
desquamated intestinal epithelial cells which are derived from the rapid turnover of 
intestinal cells. Although the entire length of the small intestine has the capability to 
absorb cholesterol from the lumen, the main sites of absorption are the duodenum 
and the proximal jejunum (Charlton-Menys and Durrington, 2008). In humans, 30-
50% of the luminal cholesterol is absorbed and returned to the liver, while the rest is 
eliminated with feces (Turley and Dietschy, 2003). The principal sites of cholesterol 
biosynthesis are the liver and the intestine. To maintain body cholesterol 
homeostasis, metabolic adaptations of endogenous de novo synthesis and/or 
catabolism are required in response to fluctuations in dietary intake of 
cholesterol.(Levy et al., 2007). 
The hydrophobicity of cholesterol is related to the main problems associated with 
increased plasma cholesterol concentrations, i.e., atherosclerosis. Atherosclerosis is 
at the origin for the majority of cases of coronary heart disease and represents the 
most prevalent cause of death in industrial countries (Ross, 1995). 
The development of atherosclerosis is a process starting already early in life, 
possible even in utero (Napoli et al., 1997). Lipids, such as cholesterol, transported 
from lipoproteins, accumulate in macrophages on vessel walls (Kruth, 2001). 
Macrophage cholesterol accumulation converts the macrofages into so-called foam 
cells and stimulates the macrophages to secrete proteases and tissue factor that 
contribute to plaque rupture and thrombosis (Zhao et al., 2006). 
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2. Intestinal Cholesterol Metabolism 
2.1. Intestine Generalities 
The intestine controls the uptake of water, electrolytes and nutrients as well as 
secretes ions, enzymes and mucus and excretes endogenous and exogenous 
compounds from the blood towards the lumen. The barrier function of the intestine 
is ensured by intestinal mucosa, with inc1udes the epithelial cells with the 
specialized tight-junction complexes that line the luminal surface. Intestinal motility 
and micelles cause mixing of the components and ensure absorption and transport 
along the tract (Scoville et al., 2008). 
The morphology of the small intestine influences the absorptive process given its 
anatomie and physiologie features. Among these are the considerable length of the 
small intestine (7 min humans and 90 cm in the rat) (Kaminsky and Zhang, 2003), 
the distribution of the metabolically competent epithelium as a mono layer of 
enterocytes and the amplification of the luminal surface by numerous finger-like 
projections of enterocyte-lined villi and, at their bases, buried crypts. Enterocytes 
have a very limited life span: after the division of stem cells at the base of the crypt, 
epithelial cells migrate up to the crypt surface, a process that takes 4 days in humans 
(3 in rodents). The cells then migrate to the villous tip, where they shed, a passage 
of 3 days in humans and 2 days in rodents (Kaminsky and Zhang, 2003). 
Each region of the intestinal tract consists of the same layers: serosa, muscularis, 
submucosa and mucosa. The mucosa is lined by a continuous layer of epithe1ial 
cells, consisting of enterocytes and goblet cells. Anatomically, the intestine is 
divided into duodenum, jejunum, ileum and colon. In each of these regions, the 
enterocytes display particular sets of enzymes and transporters that, as part of the 
homeostatic function of the intestine, are able to metabolize and transport 
endogenous and exogenous compounds (Doherty and Charman, 2002). 
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2.2. Cholesterol Biosynthesis and Esterification: HMG-CoA-reductase and 
AC AT 
Although the structure of cholesterol suggests a complex biosynthetic pathway, the 
entire formation starts with the acetate precursor. 
The first step in this pathway is the formation of 3-hydroxy-3-methylglutaryl-CoA 
(HMG-CoA) from acetyl-CoA and acetoacetyl-CoA, catalyzed by the enzyme 
HMG-CoA synthase. This is followed by the enzymatic action of HMG-CoA 
reductase to reduce HMG-CoA to mevalonate, wich represents the major rate-
controlling step in cholesterol synthesis. Currently, HMG-CoA reductase IS 
considered the rate-limiting key enzyme of the entire process. Mevalonate IS 
converted into isopentenyl-5-pyrophosphate, followed by condensation to squalene 
and conversion into lanosterol, which is an immediate precursor of cholesterol. To 
convert lanosterol into cholesterol, the entire process involves 19 reactions 
(Goldstein and Brown, 1990). 
In mammalians, HMG-CoA reductase is a glycoprotein of ~ 1 00 kDa. It shows an 
amino-terminal domain containing seven hydrophobic regions able to anchor the 
protein in the endoplasmic reticulum membrane, and a carboxy-terminal catalytic 
domain, which projects into the cytosol (Liscum et al., 1983). Virtually, every tissue 
and organ can synthesize cholesterol from acetyl-CoA (Dietschy and Siperstein, 
1967; Spady and Dietschy, 1983), but the liver and intestine are considered as the 
major sites (Taylor et al., 1960; Dietschy and Gamel, 1971; Turley et al., 1981). 
7 
mevaJonàtè' 
,. ~ '. t '" 
Figure 2. Summary of cholesterol biosynthesis (Adapted from (Charlton-Menys and 
Durrington, 2008). Cholesterol is an essential molecule in many animaIs, inc1uding 
humans, but is not required in the mammalian diet. AlI cells can synthesize it from 
simple precursors. (Adapted from Lehninger et al., 2002) 
HMG-CoA reductase is subject to both short and long-tenn controls (Goldstein and 
Brown, 1990). Long-tenn effects are mediated through alterations in its rate of 
synthesis and degradation. Short-tenn actions involve allosteric effects and 
alterations in its state of phosphorylation. Expression of HMG-CoA reductase and 
other enzymes in the cholesterogenic pathway is transcriptionally controlled by the 
sterol regulatory binding protein SREBP-2. Both expression and activity of the 
enzyme are rapidly reduced under conditions of high intracellular sterol 
concentrations (Nakanishi et al., 1988). 
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After biosynthesis and/or uptake by the enterocyte, cholesterol is mainly esterified 
at C3 with fatty acids to form cholesteryl ester, a reaction catalyzed by acyl-
coenzyme A:cholesterol acyltransferase 2 (ACAT-2) (Joyce et al., 1999). Two 
ACAT genes (acat-l and acat-2) have been identified in mammals; the two 
enzymes may function in distinct and complementary manners (Chang et al., 1997; 
Farese, 1998; Chang et al., 2001; Rudel et al., 2001). In skin cells, macrophages, 
adrena1 cells and CHO cells, ACAT-1 is the major isoenzyme and constitutes 90% 
or more of the total cellular ACAT activity. In intestinal mucosal cells, ACAT -2 is 
the major isoenzyme. ACAT-2 may be allosterically regulated by cholesterol 
(Chang et al., 2000; Liu et al., 2005). 
The objective of cholesterol esterification is the storage of cholesterol as cholesteryl 
esters in cytoplasmic lipid droplets. Cholesteryl esters can be hydrolyzed when 
necessary and the esterification/hydrolysis cycle provides cells with short-term 
buffering capacity for cholesterol. In contrast to cholesterol, plant sterols being poor 
substrates for ACAT-2, are not efficiently esterified and remain in majority 
unesterified. (Field and Mathur, 1983; Joyce et al., 1999; Temel et al., 2003). This 
reflects the main difference between plant sterols and cholesterol in all reactions 
taking place in the enterocyte. Cholesteryl esters can subsequently be secreted into 
the lymph after their packaging into chylomicrons, to ultimately reach the liver 
(Chang et al., 2006). 
2.3. Cholesterol Biosynthesis Regulation: SREBP 
Cholesterol biosynthesis is controlled by a family of transcription factors of the 
helix-loop-helix family designated Sterol Regulatory Element Binding Proteins 
(SREBPs). SREBPs activate the expression of more than 30 genes required for the 
synthesis of cholesterol, fatty acids, triglycerides and phospholipids, and are thus 
considered key regulators of cholesterogenesis and lipogenesis (Brown and 
Goldstein, 1997; Horton and Shimomura, 1999; Edwards et al., 2000; Sakakura et 
al.,2001). 
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SREBPs are encoded by two genes, srebp-l and srebp-2. Alternative promoter 
usage and alternative splicing of SREBP-l drive the production of two isoforms, 
SREBP-Ia and SREBP-Ic. The 29 additional amino acids present in the SREBP-Ia 
NH2 terminus are enriched in acidic residues and might be responsible for the 
higher transcriptional activity of SREBP-I a, compared with that of SREBP-I c. 
SREBP-Ic was initially cloned in rats and called adipocyte determination and 
differentiation factor-l (ADD 1) (Rosen and Spiegelman, 2000). 
SREBP-I a has been mainly studied in celllines, showing a strong expression, while 
in animal tissues its expression is re1atively weak. SREBP-I c, highly expressed in 
liver, is the key regulator of lipogenesis and enhances transcription of genes 
encoding acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), stearoyl-CoA 
desaturase 1 (SCD-l) and glycerol-3-phosphate acyltransferase (GPAT), all 
important enzymes in the lipogenic pathway. SREBP-2, predominantly expressed in 
celllines, is also present in the liver and adipose tissue, but overall has a rather weak 
expression in animal tissues. It activates cholesterol synthe sis by inducing 
expression of genes encoding enzymes that catalyze the various steps in cholesterol 
synthesis, including HMG-CoA reductase (Desvergne et al., 2006). 
SREBPs are synthesized as inactive precursors of ~125-kDa, bound to the 
endoplasmic reticulum (Hua et al., 1995). In order to reach the nucleus and act as 
transcription factors, their NH2-domains must be cleaved. One protein required for 
the transfer of SREBP to the nucleus is an escort protein designated SREBP 
cleavage activating prote in (SCAP). A schematic representation of SREBP 
activation is shown in Figure 3. 
Sterol (bincl. 
SCAP, prevents 
release of SREBP) 
Cleavage 
by!'irst 
p~teàse 
Cleavàge 
hy second 
prot-ease 
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Figure 3. SREBP activation. Sterol regulatory element-binding proteins are 
embedded in the ER when first synthesized, in a complex with the protein SREBP 
cleavage-activating prote in (N and C represent the amino and carboxyl termini of 
the proteins). When bound to SCAP, SREBPs are inactive. When sterol levels 
decline, the complex migrates to the Golgi complex, and SREBP is cleaved by two 
different proteases in succession. The liberated amino-terminal domain of SREBP 
migrates to the nucleus, where it activates transcription of sterol-regulated genes. 
(Adapted from Lehninger et al., 2001) 
Low membrane cholesterol levels lead to the transport of SCAP/SREBP to the 
Golgi membrane where activation of the site 1 serine protease results in a first 
cleavage. A second enzyme, the site 2 metalloproteinase, completes the maturation 
of SREBPs and releases the 68-kDa NH2-terminal domain of SREBP from the 
membrane (Edwards et al., 2000). This fragment contains a basic helix loop helix 
(HLH) leucine zipper domain, which functions as a transcription factor upon 
translocation into the nucleus. The mature forms of SREBPs bind to elements 
initially characterized as featuring an enhancer sequence called E-box that is 
recognized by members of the HLH transcription factor family. SREBPs also bind 
to sites related to the direct repeat TCANCCAC (Horton et al., 2002). 
Deletion of SREBP-l (eliminating both SREBP-la and SREBP-lc) or SREBP-2 
leads to partial or fully embryonic lethality, respectively. In contrast, specific 
deletion of the SREBP-l c transcript is not lethal, suggesting an important role of 
SREBP-la and SREBP-2 in embryonic development. The SREBP maturation 
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process via membrane cholesterol sensing is consistent with their important role in 
cholesterol homeostasis (Sundqvist and Ericsson, 2003). SREBP-2 is mainly 
involved in cholesterol metabolism. SREBP-lc has an important implication in fatty 
acid synthe sis, whereas SREBP-l a is involved in cholesterol and fatty acid synthesis 
(Desvergne et al., 2006). 
3. Intestinal Cholesterol Transport 
Next to endogenous synthe sis, dietary intake provides the other main source of 
cholesterol in mammals. Only a fraction of dietary cholesterol is absorbed in the 
small intestine, with large interindividual variations in humans. Reported values 
range from 25% to 85% (Sehayek et al., 1998; Bosner et al., 1999). In contrast, only 
small amounts of plant sterols are absorbed (Lu et al., 2001b; Turley and Dietschy, 
2003). 
Recent studies suggest that cholesterol absorption is a protein-mediated process. In 
support to this hypothesis, cholesterol uptake by apical membranes in vitro follows 
a second-order reaction kinetics changing to a low-affinity first-order kinetics 
mechanism upon proteolytic digestion of proteins on the surface of the brush-border 
membranes (Thurnhofer and Hauser, 1990). The recent discovery of inhibitors (that 
selectively block cholesterol absorption at very low doses) and their binding to 
intestinal mucosa in a specific and saturable manner, supports the protein-mediated 
cholesterol absorption hypothesis (Hemandez et al., 2000). 
Various transporters, inc1uding fatty acid translocase/c1uster determinant 36 
(FAT/CD36), scavenger receptor c1ass B type l (SR-BI) and Niemann Pick Cl-
Likel (NPCILl) may be involved in cholesterol uptake, while the ATP Binding 
Cassette transporter family, inc1uding several cholesterol carriers (ABCAl, ABCBl, 
ABCG5/G8), may act as efflux pumps favoring cholesterol export out of absorptive 
cells into the lumen or basolateral compartments (Levy et al., 2007). 
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Intestinal cholesterol absorption consists on a multistep process that can be 
controlled at several leve1s. A schematic overview of the absorption process is 
shown in Figure 4. 
Cholesterol 
~~~8 >>>>>~8-' - Chol 
Qo-Ol),r ! 
HDL 
- Chol~ 
/ 
\ . ~ -1 .. ÀBCG5IG8 
denovo 
LDL ---... a Ldlrsynthesis .. 
Lrp 
Cholesterol 
Figure 4. Schematic overview of cholesterol transport in enterocytes. 
ABCAl/G5/G8, ABC-transporters Al,G5 and G8; ACAT2, acyl-coenzyme 
A:cholesterol acyltransferase-2; CE, cholesteryl ester; Chol, cholesterol; HDL, high 
density lipoprotein; LDL, low density lipoprotein; LDLr, LDL-receptor; LRP, LDL-
receptor related prote in; NPClLl, Niemann-Pick Cl like 1, CD36, c1uster 
determinant 36; SR-BI, scavenger receptor c1ass B type I. (Adapted from (Levy et 
al., 2007) 
After cholesterol is taken up by the enterocyte, it is esterified by the action of acyl-
coenzyme A:cholesterol acyltransferase 2 (ACAT2) (Lee et al., 2000). Cholesteryl 
esters are packed into chylomicrons and subsequently secreted via the lymph to the 
circulation (Wang and Carey, 2003). 
In addition, studies have shown that enterocytic cholesterol can also be transferred 
to lipid-poor apoA-I through the action of intestinal ABCAI (Brunham et al., 2006). 
The HDL partic1es are directly excreted into the circulation and contribute for 
approximately 30% to the steady-state plastna HDL pool in mice (Brunham et al., 
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2006). However, abcar/- mice do not show reduced cholesterol absorption 
(McNeish et al., 2000; Drobnik et al., 2001), indicating that this process is not of 
regulatory relevance for mass cholesterol absorption. Non esterified cholesterol and 
plant sterols can be excreted from the enterocyte back into the intestinal lumen. This 
process is facilitated by the ABC half-transporters ABCG5 and ABCG8 (Berge et 
al., 2000; Igel et al., 2003). Overexpression of these transporters in mice increases 
excretion of cholesterol into the lumen and limits net cholesterol absorption (Yu et 
al., 2002b). 
3.1. Cholesterol Transporters 
Considerable effort has been spent over the past several years on identifying the 
cholesterol transporter(s) in enterocyte membranes. This section focuses on recent 
progress and explanatory findings associated to various pro teins that are potentially 
involved in cholesterol transport. 
3.1.1. Scavenger Receptors CD36 and SR-BI 
Several cell surface glycoproteins, inc1uding CD36 and SR-BI are designated as 
scavenger receptors and contribute to the uptake of modified lipoproteins (Ades et 
al., 1992; Calvo et al., 1995; Acton et al., 1999; Nakata et al., 1999; Husemann et 
al.,2001). 
3.1.1.1. CD36 
FAT/CD36, (fatty acid translocase/c1uster determinant 36) an 88-kDa membrane 
glycoprotein, is found in several cell types, inc1uding platelets, monocytes, 
macrophages and endothelial cells where it facilitates cellular uptake of long-chain 
fatty acids. In humans and mice, CD36 is also expressed in intestinal epithelial cells. 
(Ohgami et al., 2001; Nicholson and Hajjar, 2004). 
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CD36 has been reported to be a multifunctional receptor recognizing severalligands 
inc1uding OxLDL (Nakata et al., 1999; Nozaki, 1999), thrombospondin (Simantov 
and Silverstein, 2003), collagen (Femandez-Ruiz et al., 1993; Kopprasch et al., 
2004), Plasmodium jalciparum-infected erythrocytes (Beeson and Brown, 2004) 
and anionic phospholipids (Ryeom et al., 1996; Bottcher et al., 2006). The 
importance of CD36 in fatty acid absorption is well established, since CD36 
deficiency leads to abnonnallipid processing in enterocytes. 
The potential role of CD36 in cholesterol absorption is reported in studies showing 
enhanced cholesterol uptake from micellar substrates by CD36-transfected COS-7 
cells compared to mock-transfected cells (van Bennekum et al., 2005). The CD36-
mediated cholesterol uptake properties in the transfected cells are similar to that 
observed with SR-BI-transfected cells as well as those observed with brush-border 
membrane vesic1es prepared from wild-type mice (van Bennekum et al., 2005). The 
importance of CD36 in mediating cholesterol absorption was demonstrated in a 
study that showed a significant reduction of cholesterol transport from the intestinal 
lumen to the lymph in CD36-null mice (Nauli et al., 2006). Interestingly, the CD36-
facilitated cholesterol uptake process is similar to that observed for SR-BI-mediated 
cholesterol uptake in their sensitivity to ezetimibe inhibition (van Bennekum et al., 
2005). 
3.1.1.2. SR-BI 
SR-BI, the scavenger receptor c1ass B type l, an 82-kDa protein, is highly expressed 
in the small-intestine brush border membrane where it facilitates the uptake of 
dietary cholesterol from either bile salt micelles or phospholipid vesic1es (Hauser et 
al., 1998). SR-BI is able to bind with fair but different affinities to HDL, LDL, and 
modified (acetylated or oxidized) LDL. On the other hand, HDL and LDL appear 
not to share the same binding sites (Gu et al., 2000). 
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The participation of SR-BI in cholesterol absorption was suggested by studies that 
showed that SR-BI cDNA-transfected cells displayed increased cholesterol uptake 
from micellar substrates compared with mock-transfected cells with low SR-BI 
expression (Altmann et al., 2002; van Bennekum et al., 2005). Moreover, the 
increase in cholesterol uptake by SR-BI-transfected cells showed a sensitive effect 
to ezetimibe inhibition in both of these studies. 
Despite the strong evidences suggesting that SR-BI may participate in cholesterol 
absorption on the surface of brush-border membranes, its role in cholesterol 
absorption in a physiological environment remains controversial. Since scarbr/-
mice, with a disruption of the sr-bi gene, efficiently absorbed cholesterol, in similar 
fashion to wild-type mice (Altmann et al., 2004), whereas cholesterol absorption 
was increased in transgenic mice with SR-BI-specific overexpression in the intestine 
(Bietrix et al., 2006). 
3.1.2. NPCILl 
Niemann-Pick Cl-like 1 prote in (NPClLl), a l5l-kDa prote in, is expressed 
predominantly in the gastrointestinal tract with peak expression in the proximal 
jejunum (Altmann et al., 2004; Davis et al., 2004). In situ hybridization and 
immunohistochemistry analysis of the jejunum revealed discrete NPClLl 
localization to the epithe1iallayer lining the luminal space along the crypt-villus axis 
(Altmann et al., 2004). Furthermore, our group (Sane et al., 2006) was able to assign 
NPClLl to the brush-border membrane with the use of cell fractionation and high-
resolution immunoelectron microscopy. The protein was also found to be located in 
subcellular compartments of the human enterocyte, inc1uding lysosomes and 
mitochondria (Sane et al., 2006). 
NPClLl has 50% ammo acid homology to NPCl, which is defective in the 
cholesterol storage disease Niemann-Pick type C (Carstea et al., 1997). A strong 
support for the essential role that NPC 1 L 1 plays in intestinal cholesterol absorption 
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lies in the following examples. Mice deficient in NPCILI lack the ability to absorb 
cholesterol and exhibit prevailing protection against the rise in plasma and hepatic 
cholesterol associated with the administration of high cholesterol diets (Altmann et 
al., 2004; Davis et al., 2004; Davis et al., 2007). Genetic modifications of NPCILI 
in cultured intestinal cells alter cholesterol uptake (Palmer et al., 1995; Yu et al., 
2006; Yamanashi et al., 2007). Reduced expression in NPCILI was found 
associated with reduced sterol absorption, low-density lipoprotein-cholesterol 
(LDL-C) levels (Cohen et al., 2006) and LDL-C response to ezetimibe therapy 
(Hegele et al., 2005; Simon et al., 2005; Wang et al., 2005). Inactivation ofNPCILI 
led to defects in cholesterol transport, variations in key regulatory sterol enzymes 
(HMG-CoA reductase and ACAT), and high gene expression of SREBP, which 
suggest key roles for NPCILI in cholesterol homeostasis (Sane et al., 2006). 
3.1.3. ATP-Binding-Cassette (ABC) Transporters 
ABC-transporters compnse a large family of membrane proteins that mediate 
transport of a variety of compounds across cellular membranes against 
concentration gradients at the cost of ATP. Most ABC-transporters contain two 
transmembrane and two ATP-binding domains. Genes that encode for the ABC 
transporters are conserved from bacteria to mammals. They play critical roles in the 
active transport of a wide range of molecules across cellular membranes. Each ATP-
binding domain contains the conserved Walker A and Walker B motifs that are 
involved in ATP binding and hydrolysis. Each transmembrane domain consists of 
six membrane-spanning a-helices. Sorne ABC-transporters contain only a single 
transmembrane and a single ATP-binding domain and are therefore called "half-
transporters". These half-transporters assemble either as homo di mers or 
heterodimers to create a functional transporter (Dean et al., 2001; Borst and 
Elferink, 2002; Tusnady et al., 2006). Three specific ABC transporters of relevance 
for this study are discussed below. 
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3.1.3.1. ABCAI 
ABCA1, a full-sized transporter, is probably the most extensively studied 
transporter of the ABC superfamily. ABCA1 is expressed in virtually aIl organs and 
tissues, with a high expression in hepatocytes, enterocytes and macrophages 
(Luciani et al., 1994; Wellington et al., 2002). The ABCA 1 protein is located on the 
basolatera1 surface of intestinal cells, indicating that this protein does not have a 
direct role in cholesterol absorption from the intestinal lumen. CUITent studies 
indicate that ABCA 1 expression in the basolatera1 membrane is crucial for intestinal 
secretion of HDL, which accounts for ~30% of HDL production in the body (Attie, 
2007). ABCA1 mediates the efflux of cholesterol and phospholipids ABCG5/G8 to 
lipid-poor apoA-I and to pre-p-HDL. Therefore, ABCA1 has a crucial role in HDL 
formation, as evidenced from the discovery of mutations in the ABCA 1 gene in 
Tangier disease (Bodzioch et al., 1999; Brooks-Wilson et al., 1999; Rust et al., 
1999). Tangier patients, as weIl as mice lacking ABCA1, are characterized by an 
almost complete absence of HDL and accumulation of cholesteryl esters in various 
tissues. 
However, it is important to note that ABCA1, present in other tissues promotes 
reverse cholesterol transport to the li ver for biliary excretion (Vaisman et al., 2001). 
Therefore, ABCA 1 may indirectly impact on cholesterol absorption through the 
modulation of lipid composition in bile and the intestinal lumen, as evidenced by the 
moderately lower cholesterol absorption in abcal-I-) mice. 
3.1.3.2. ABCG5 and ABCG8 
Two groups (Berge et al., 2000; Lee et al., 2001) independently identified the two 
adjacent genes ABCG5 and ABCG8, in a head-to-head configuration that encode 
transporters, highly expressed in the liver and intestine. Unlike other ABC 
transporter genes that encode proteins with 12 transmembrane domains, ABCG5 
and ABCG8 separetely encode a protein with 6 transmembrane domains, and the 
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heterodimerization of the two encoded proteins is required for transport activity 
(Graf et a1., 2002). 
ABCG5 and ABCG8 are localized at the apical brush border membranes of 
enterocytes and the canalicular membranes of hepatocytes. These transporters 
constitute an efficient efflux pump system for cholesterol and plant sterols 
transporting out of intestinal cells back into the intestinal lumen and from 
hepatocytes into the bile. These efflux processes thus contribute to the regulation of 
intestinal absorption and biliary secretion of cholesterol and plant sterols (Yu et al., 
2002a; Yu et al., 2002b; Yu et al., 2003; Klett et al., 2004). 
Mutations in either one of these genes cause sitosterolemia, an error of metabolism 
characterized by the accumulation of plant sterols in the body due to a decreased 
ability for their hepatobiliary secretion (Berge et al., 2000; Lee et a1., 2001; Lu et 
a1., 2001a). Accordingly, mice deficient for ABCG5 and/or ABCG8 are 
characterized by accumulations of plant sterols in blood and organs. These mice 
have a reduced secretion and a clearly enhanced intestinal absorption of plant 
sterols, whereas absorption of cholesterol is not affected (Yu et a1., 2002a; Klett et 
aL, 2004; Plosch et al., 2004). 
However, overexpression of ABCG5 and ABCG8 in transgenic mice causes a poor 
fractional intestinal cholesterol absorption besides the increased hepatobiliary 
cholesterol secretion (Yu et aL, 2002b). These findings have established ABCGS 
and ABCG8 as key transporters that regulate excretion of cholesterol and plant 
sterols from the body. 
4. Transcription Factors 
One type of metabolic regulation relies on the transcriptional regulation mechanism, 
which affects the level of expression of key enzymes and/or proteins and is effective 
on a long time scale. Transcriptional control requires specific signaIs, called 
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transcriptional factors, to be transduced to the cell nucleus where defined sets of 
genes are targeted. 
Transcription factors are soluble proteins that are able to bind to DNA. Their 
binding to promoter sites of genes influences the transcription of these genes, 
leading to an up- or down-regulation of their expression. Sorne transcription factors 
need to be activated by ligands before they are targeted to the nucleus (Des vergne et 
al., 2006). A schematic model of this type of transcriptional regulation is given in 
Figure 5. 
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Nucleus 
00 
Promoter reglon 
Figure 5. General schema of gene regulation by tranSCrIptIOn factors. TF, 
transcription factor. (Adapted from Bandsma et al., 2004) 
Several food components and derivatives thereof may act as ligands for specifie 
transcriptional factors, providing means to adapt gene expression patterns in 
response to environmental (i.e., dietary) signaIs. The distinct roles of certain factors 
important in transcriptional control of genes involved in cholesterol, lipid and bile 
acid metabolism made them highly interesting as potential phannacological targets 
for prevention or treatment of certain diseases. 
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Transcriptional factor proteins exhibit a characteristic structure with regions of 
conserved sequence and function (Figure 6A) (Francis et al., 2003). The proteins 
contain an NH2-terminal region that harbors a ligand-independent transcriptional 
activation function (AF-1). Adjacent is the DNA binding domain (DBD), containing 
two highly conserved zinc finger motifs that target the receptor to specifie DNA 
sequences. This is followed by a region that permits protein flexibility to allow 
simultaneous receptor dimerization and DNA binding. Close to the COOH-terminal 
region is the usually highly conserved ligand-binding domain, and the last part of 
the receptor contains a ligand-dependent activation function (AF-2) (Chawla et al., 
2001; Germain et al., 2006). Transcriptional factors can bind to DNA response 
elements in the promotor regions of their target genes as monomers, homodimers or 
as heterodimers with the Retinoid X Receptor (RXR) (Figure 6B) . 
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Ligand binding [ 
. domain 
DNAbi~ding [ 
domain 
l'"''''''''~~ ........ ...., 
..... ------..... 
. Transcription. 
. ofgenes ... . 
c 
Figure 6. Schematic structure of transcriptional factors. (A) Organisation of a 
transcriptional factor. AF, activation function; DBD, DNA-binding domain; LBD, 
Ligand-binding domain. (B) Heterdimerization and DNA-binding of transcriptional 
factors. (Adapted from Edwards et al., 2000) 
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4.1. The Liver X Receptor (LXR) 
The liver X receptor is a major player in regulating cholesterol metabolism. Two 
LXR isotypes have been identified in mammals, i.e., LXRa (NRIH3), which is 
predominantly expressed in the liver, kidney, intestine, adipose tissue, and 
macrophages, and LXRp (NR 1 H2) with a more ubiquitous expression pattern 
(Willy et al., 1995; Peet et al., 1998). These two isotypes, LXRa and LXRP, share 
77% ami no acid identity in their DBD and LBD and are highly conserved between 
rodents and human. 
LXR endogenous activators are oxysterols, i.e., cholesterol metabolites (Janowski et 
al., 1996; Forman et al., 1997; Lehmann et al., 1997; Janowski et al., 1999). As 
such, they participate in the cholesterol sensing processes and regulate important 
aspects of cholesterol and fatty acid metabolism (Tontonoz and Mangelsdorf, 2003). 
LXRs heterodimerize with RXR to bind to their DNA response element, formed 
from a direct repeat of two hexamers related to the sequence AGTTCA, separated 
by four nuc1eotides. Mono-oxidized derivatives of cholesterol are strong LXR 
ligands. The most potent are 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 
and 24(S),25-epoxycholesterol, which activate both LXRa and LXRp. Little lS 
known about the sterol hydroxylases that produce th~se metabolites, but it lS 
assumed that oxysterol concentrations parallel those of cholesterol (Desvergne et al., 
2006). Importantly, oxysterols are found at micromolar concentrations in tissues that 
express high levels of LXRa or· LXRp. Activation of the heterodimer can also be 
triggered by RXR ligands (Field et al., 2004). LXRa and LXRp null mutant mice 
have been generated and confirm the important role of these receptors, and more 
particularly that of LXRa in cholesterol homeostasis. 
When LXRa becomes activated, the LXRalRXR complex induces transcription of 
target genes amongst which are ABCAl, ABCG5/G8. Activation of LXRa thus 
results in elevated levels of HDL-cholesterol, reduced intestinal cholesterol 
22 
absorption, increased hepatobiliary cholesterol secretion and increased neutral sterol 
10ss via the feces. In this way, LXR activation has anti-atherogenic actions, as has 
been substantiated in a mouse model that is susceptible to develop atherosclerosis 
(ldl-r -/) treated with a synthetic LXR agonist, T090131773 (Goodwin et al., 2008). 
However, besides stimulation of cholesterol disposaI, activation of LXR by 
synthetic ligands like T090 1317 also leads to increased lipogenesis, 
hypertriglyceridemia through the production of larger VLDL partic1es and hepatic 
steatosis in rodents (Grefhorst et al., 2002). Therefore, general LXRa activation can 
only be used as an atheroprotective therapy if the undesirable effects on lipogenesis 
can be eliminated by the development of selective LXR modulators. 
4.2. Peroxisome Proliferator-Activated Receptors (PP AR) 
pp ARs were the first nuclear receptors identified as "sens ors" rather than classic 
hormone receptors. They are molecules that control a variety of genes in several 
pathways of lipid metabolism (De Vos et al., 1995). Three mammalian peroxisome 
proliferator-activated receptors (PPARs) have been cloned in Xenopus, rodents, and 
humans: PPARa (NRIC1), PPARp/ô (NRIC2) and PPARy (NRIC3). Two PPARy 
isoforms, PPARyl and PPARy2, are splice variants in their NH2-terminal domain. 
They are aIl activated by polyunsaturated fatty acids and eicosanoids and are 
therefore considered to be fatty acid sens ors (Willson et al., 2000). AlI PP ARs play 
important roles in the control of lipid and glucose metabolism and have been 
involved in obesity-related metabolic diseases, such as hyperlipidemia, insulin 
resistance, and coronary artery disease. pp ARs, which recognize and bind a variety 
of fatty acids, regulate mcst of the pathways linked to lipid metabolism (Michalik et 
al., 2003). 
pp ARa is most highly expressed in tissue with high activity levels of lipid 
catabolism, e.g., liver, brown adipose tissue, and skeletal and heart muscle and was 
recognized to be responsive to fibrates, which are widely used drugs for treatment of 
hyperlipidemia (Issemann et al., 1993; Schonfeld, 1994). Activated PPARa 
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increases p-oxidation of fatty acids, thereby stimulating energy production and 
preventing lipid accumulation. Under the physiological fasting condition, pp ARa 
becomes activated by the free fatty acids re1eased from adipose tissue, after which 
hepatic p-oxidation is induced in order to provide energy to peripheral tissues 
(Kersten et al., 1999). 
PPARy is mainly expressed in the adipose tissue and is involved in adipocyte 
proliferation. PPARy1 is mainly expressed in adipose tissues but is also detected in 
the colon, spleen, retina, hematopoeitic celIs, and skeletal mùscle. PPARy2 has been 
found mainly in the brown and white adipose tissue. PPARy is critical for the 
maintenance of glucose homeostasis and is a molecular target of thiazolidinediones 
(TZDs), a class ofinsulin-sensitizing drugs (Ros en and Spiegelman, 2001). 
pp ARp has an ubiquitous expression pattern and appears to serve several functions. 
Besides its role in lipid metabolism, it is involved in skin biology, energy 
homeostasis and inflammatory processes (Michalik et al., 2003). pp ARp was 
reported as an important factor in the regulation of glucose metabolism and insulin 
sensitivity (Lee et al., 2006). 
The ligand binding pocket of pp ARs is much larger than that of the other nuclear 
receptors and relatively easily accessible. The DNA binding domain is extremely 
weIl conserved. The less conserved NH2-terminal region bears a ligand-independent 
activation domain, at least in PPARa and PPARy (Xu et al., 2001a; Xu et al., 
2001b; Xu et al., 2002; Xu et al., 2004). 
pp ARs bind to DNA as heterodimers with RXR, on pp AR response elements 
(PPRE) comprising direct repeats of two hexamers closely related to the sequence 
AGGTCA and separated by one nucleotide. The five nucleotides that flank the 5'-
end of this core sequence are also important for the efficiency of pp ARa:RXR 
binding (Desvergne et al., 2006). 
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The first molecules to be recognized as pp ARa activators, and later characterized as 
ligands, belong to a group of molecules that induce peroxisome proliferation in 
rodents, thus explaining the name of peroxisome proliferator activated receptor 
given to this receptor. This diverse group of substances includes, for example, sorne 
plasticizers and herbicides. More interestingly, various fatty acids, more particularly 
unsaturated fatty acids, and sorne eicosanoids mainly derived from arachidonic acid 
and linoleic acid, bind to PPARa, -~, and -y with varying affinities (Desvergne et al., 
2006). In addition to being activated by fatty acids, pp ARa responds to fibrates that 
are hypolipidemic drugs, and pp ARy responds to thiazolidinediones that are insulin 
sensitizers, demonstrating their potential as drug targets. In the process of 
transcriptional regulation, ligand-bound pp ARs recruit coactivators, most likely 
organized in large complexes (Surapureddi et al., 2002). Co factor recruitment may 
be pp AR isotype specifie and may ensure the specificity of target gene activation. In 
addition to pp AR ligand binding, pp ARs can also be activated by phosphorylation 
of serines located in the AlB domain, and the pp AR:RXR heterodimer can be 
activated by RXR ligands (Desvergne et al., 2006). 
4.3. The Retinoid X Receptor 
Retinoid X receptors (RXRs; NR2B 1) play an important role in nuclear receptor 
signalling, as they function as general partners for a variety of nuclear hormone 
receptors that bind as heterodimers to DNA. There are three isotypes of RXR, a, ~, 
and y, and several isoforms for each of them (Chambon, 1996). Each isotype and 
isoform has its specifie expression pattern. However, each single tissue contains one 
or several forms of RXR. 
Almost aIl the nuclear receptors are active as heterodimers with RXR. The 
important part that RXR may play is further emphasized by the fact that RXR is 
itself a nuclear receptor that can be activated by specifie ligands. PPAR:RXR and 
LXR:RXR are permissive heterodimers: RXR can bind its own ligand, in the 
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absence of a ligand for its partner and can thereby activate the transcription of the 
heterodimer target genes (Desvergne et al., 2006). 
In addition to the various heterodimers for which RXR is an obligatory partner, 
RXR can form homodimers. The in vivo relevance of these homodimers is still 
under study. RXR can be activated by 9-cis-retinoic acid, an isomer of all-trans-
retinoic acid (Heyman et al., 1992). Retinoids are used for treatment of 
dermatological disorders and certain cancers and a common side-effect of this 
treatment is dyslipidemia (Farol and Hymes, 2004), indicating that retinoids and 
RXR are involved in the regulation of lipid metabolism. 
Deletion of the RXRa gene in the liver allowed the identification of the most 
affected pathways (Wan et al., 2000). As expected, many PPARa-mediated 
functions were altered and the activity of LXR and FXR was also compromised, 
suggesting that the absence of RXRa cannot be compensated by RXR~ and RXRy 
in the liver. 
5. Glucose metabolism 
Carbohydrates are a main source of energy and can be stored in the form of starch in 
plants and glycogen in animaIs. Carbohydrates are also part of the structural 
framework of both DNA and RNA and form structural elements' in cell walls of 
bacteria and plants. An important group of carbohydrates comprises the 
monosaccharides of which glucose is an example. Glucose is primordial for the 
generation of energy. Monosaccharides are aldehydes or ketones with two or more 
hydroxyl groups, that can be described by the formula (CH20)n. Glucose 
metabolism is tightly regulated in humans and animaIs to guarantee a sufficient 
glucose supply to glucose-dependent organs. The brain is the organ that is most 
dependent on an adequate supply of glucose, since it can only use ketone bodies as 
an alternative energy source and this only to a limited extent. Carbohydrates are 
transported to and from various tissues through the blood compartment. Glucose can 
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enter the blood via two routes, i.e., dietary glucose derived from the intestine and 
glucose production by the liver and the kidney. During fasting, the organism will 
solely depend on the production of glucose, mainly by the liver. Glucose can be 
produced directly through gluconeogenesis from various substrates, such as certain 
amino acids, lactate and glycerol. The liver is also able to produce glucose indirectly 
through phosphorylation of glycogen, the storage form of glucose. This process is 
called glycogenolysis (Rothman et al., 1991; Hellerstein et al., 1997). Glucose can 
also be taken up first by the blood, phosphorylated by glucokinase to form glucose-
6-phosphate (G6P) and then be secreted again after dephosphorylation by glucose-6-
phosphatase (G6Pase). This process is called glucose cycling (Jens sen et al., 1990). 
5.1. Physiological interactions between carbohydrates and lipid metabolism 
Carbohydrate metabolism and lipid metabolism are linked in many ways. First of 
all, mammals are capable of tuming glucose into fat. Glucose is degraded, through 
glycolysis, into acetyl-CoA, which is the precursor for fatty acid synthesis. On the 
other hand, fat cannot be tumed into glucose by mammals, because the enzyme 
system for this conversion is lacking. Evidence was generated in the sixties by the 
group of Dr. Randle evidencing that fat oxidation inhibits glucose oxidation, by 
interference at multiple levels (Randle et al., 1963). The key enzyme in this 
inhibitory process is pyruv~te dehydrogenase, which catalyzes the oxidative 
decarboxylation of pyruvate leading to the formation of acetyl-CoA. It was found 
that free fatty acids (FF A) increase concentrations of acetyl-CoA as well as of 
citrate, important in the citric acid cycle (Randle et al., 1963). Acetyl-CoA was 
found to decrease pyruvate dehydrogenase allosterically and citrate was found to 
inhibit phosphofructokinase, an enzyme involved in glycolysis. This whole process 
came to be known as the glucose-fatty acid cycle or Randle cycle. More recently, 
the group of Dr. Robert Wolfe provided data to indicate the opposite phenomenon 
(Sidossis and Wolfe, 1996). Using a hyperinsulinemic-hyperglycemic clamp 
technique they found that elevated glucose concentrations inhibited fatty acid 
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oxidation. This effect might be due to increased intracellular malonyl-CoA levels. 
Malonyl-CoA is produced from acetyl-CoA and is the first step in fatty acid 
synthesis, i.e. de novo lipogenesis. Increased glycolysis produces more pyruvate 
leading to increased acetyl-CoA production, which in turn will lead to more 
malonyl-CoA. Malonyl-CoA is known for its inhibitory effect on carnitine-
palmitoyl transferase l, an enzyme catalyzing the binding of camitine to long-chain 
fatty acids, a necessary step for entry into mitochondria and subsequent oxidation. 
Lipids and carbohydrates do not only influence each other in terms of oxidation but 
also in their synthetic processes. It has been known for sorne time that glucose is 
capable of promoting de nova lipogenesis (Groen et al., 2001). However, a high 
glucose intake probably does not promote hepatic synthesis of quantitatively 
important amounts of fatty acids in humans with a western dietary lifestyle 
(Hellerstein et al., 1996). It was found that the regulation of hepatic de novo 
lipogenesis is, at least partly, controlled by specific transcription factors. Evidence 
however shows that SREBP-1 and 2 can partially compensate each other, as 
SREBP-l knockout mice showed elevated levels of SREBP-2 and increased 
cholesterol synthesis rates (Shimano et al., 1997). Glucose is able to induce 
lipogenesis indirectly by inducing insulin secretion. Insulin has long been known for 
its lipogenic activity (Beynen et al., 1979). Two groups separately found that insulin 
has an additional effect by enhancing SREBP-lc gene expression and the abundance 
of the protein in the endoplasmic reticulum (Moon et al., 1999; Shimomura et al., 
1999; Azzout-Marniche et al., 2000). The carbohydrate responsive element binding 
prote in (ChREBP) (Foufelle et al., 1998; Koo et al., 2001), is also involved in 
transcriptional regulation of lipogenesis. ChREBP is induced in situations 
characterized by high glucose concentrations (Koo et al., 2001; O'Callaghan et al., 
2001; Yamashita et al., 2001). ChREBP itselfwas found to activate gene expression 
of both pyruvate kinase and acetyl-CoA carboxylase (Kawaguchi et al., 2001; Koo 
et al., 2001; O'Callaghan et al., 2001; Yamashita et al., 2001). 
Hepatic very-low density lipoprotein (VLDL) secretion to plasma is also a process 
in which insulin is a primary factor. Insulin, after secretion in response to a rise in 
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plasma glucose concentration, regulates VLDL-triglyceride secretion, either directly 
by influencing the rate of apoB synthesis, or indirectly via its effect on the supply of 
FFA to the liver (Sparks and Sparks, 1994b; Aarsland èt al., 1996; Sidossis et al., 
1998). The acute effects of insulin on regulation of VLDL secretion differ from its 
chronic effects. Acutely, insulin inhibits hepatic VLDL secretion (Sparks and 
Sparks, 1994b), whereas chronic exposure to insu lin has an stimulatory effect 
(Zammit et al., 1999). In addition to the regu1ation of lipid synthesis and secretion 
by carbohydrates and insulin, lipids might also promote gluconeogenesis. FF A 
stimulate hepatic glucose production. However, fasting, a situation with increased 
FF A availability, is well-known to inhibit hepatic glucose production (HGP) 
(Rothman et al., 1991; Neese et al., 1995). 
Another level of metabolic regulation by FF A might be re1ated to the transcription 
factor pp ARa. pp ARa has also been suggested to induce phosphoenolpyruvate 
carboxykinase PEPCK gene expression (Kersten et al., 1999). pp ARa knockout 
mice suffer from fasting induced hypoglycemia, indicating a possible role in control 
of hepatic glucose production (Kersten et al., 1999). Apart from pp ARa, evidence 
exists that other transcription factors are involved in regulation of glucose 
metabolism. Glucokinase expression is activated by hepatic nuclear factor-4a 
(HNF-4a) (Roth et al., 2002). Glucose, through activation phosphorylationl 
dephosphorylation of ChREBP, influences transcription of pyruvate kinase 
(Kawaguchi et al., 2001). Glucose-6-phosphatase expression is also found to be 
mediated by transcriptional mechanisms as well as by breakdown of mRNA 
(Massillon, 2001). 
In summary, transcriptional regulation is a form of metabolic regulation that is 
important for all metabolic routes of glucose. One must realize that it is likely that 
more transcription factors playing an important role in carbohydrate metabolism 
will be found in the future. 
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5.2. Pathophysiology of carbohydrate and lipid metabolism in diabetes 
Diabetes means "excessive urination". The name diabetes mellitus was given to 
patients with excessive urine production in combination with a honey-flavored taste 
of the urine, caused by urinary glucose excretion. Diabetes mellitus today comprises 
a group of metabolic disorders characterized by chronic hyperglycemia. Currently, 
three types of diabetes mellitus are known: diabetes mellitus type 1, caused by an 
autoimmune-driven destruction of pancreatic ~-cells; diabetes mellitus type 2 
(DM2), or non-insulin dependent diabetes mellitus as it mistakenly is also known. 
The third group is called maturity-onset diabetes of the young (MODY), which is a 
group of genetic diseases caused by mutations in numerous genes such as 
glucokinase and insu lin promo ter factor 1 (McGarry, 2002). DM2 is the most 
common disorder, accounting for more than 90 percent of cases, whose incidence is 
still growing in the western world even in children. The development of DM2 is in 
almost all cases caused by an overconsumption of food in relation to the energy 
expenditure and has become an epidemic disease in western societies. The primary 
event leading to full-blown DM2 is the deve10pment of insulin resistance, although 
discussion remains. Fat accumulation in muscle, liver and other tissues have been 
thought to induce insulin resistance (McGarry, 2002). Sorne researchers consider 
defective insulin secretion by the pancreas, instead of insulin resistance, to be 
primary in the development of DM2 (Ferrannini, 1998). It is, however, clear that 
insu lin resistance can precede clinically detectable DM2 by more than ten years 
(Lillioja et al., 1988), underscoring the importance of insulin resistance in the 
etiology of this disease. DM2 is associated with hyperglycemia and hyperlipidemia. 
Hyperinsulinemia occurs in the early stages of the disease when the pancreatic ~­
cells try to compensate for the insulin resistance by increasing insulin secretion. As 
the disease progresses, pancreatic ~-cell failure develops giving rise to the full-
blown DM2 phenotype. 
DM2 is also characterized by hyperlipidemia, including hypercholesterolemia and 
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Hypertriglyceridemia (Yoshino et al., 1996). Increased levels ofVLDL particles and 
small, dense LDL particles and decreased levels of HDL particles are commonly 
found (Reaven et al., 1993), giving rise to an atherogenic lipid profile. 
Increased VLDL secretion might result from the decreased sensitivity to the 
inhibitory effects on this process of insulin directly as studies in animal models of 
diabetes and diabetic humans have shown (Lewis et a1., 1993; Sparks and Sparks, 
1994a; Bourgeois et al., 1995). Increased VLDL secretion in DM2 might also be 
caused by insu lin indirectly through modulation of the supply of FF A to the liver. 
Increased FF A flux by modulation of hormone sensitive lipase, which is observed in 
insulin resistant states, has been suggested to enhance VLDL secretion by the liver. 
A number of studies have shown a diminished ability of insulin to suppress FF A 
rate of appearance in DM2 patients (Lewis et al., 2002). There is strong evidence 
that elevated FF A levels are associated with increased VLDL production in healthy 
humans (Lewis et al., 1995; Lewis, 1997). Overall, consensus practically exists that 
increased FF A flux to the liver is an important cause of overproduction of VLDL 
triglycerides by the liver in DM2. Decreased clearance of triglycerides from the 
blood in DM2 patients is related to impaired lipolysis of VLDL-triglycerides. Since 
this process is mediated by lipoprotein lipase, which is an insulin-senstivie enzyme, 
insulin resistance can lead to decreased levels of lipoprotein lipase. Multiple studies 
have shown decreased triglyceride clearance (Kissebah et al., 1982; Howard et al., 
1983), although this has not been conclusive (Blades and Garg, 1995; Yost et al., 
1995). 
Objective of Study 
Whole body cholesterol balance is regulated by the net effects of dietary cholesterol 
absorption, de novo cholesterol biosynthesis and biliary excretion from the liver 
(Davies and Ioannou, 2006; Kruit et al., 2006). 
During the last decade, it has become c1ear that cellular cholesterol transport is a 
protein-mediated process, which in tum is regulated by certain nuc1ear receptors. 
Several transporters, inc1uding fatty acid translocase/c1uster de terminant 36 
(FAT/CD36), scavenger receptor c1ass B type 1 (SR-BI) and Niemann Pick CI-Like 
1 (NPCIL1) influence cholesterol uptake. ATP Binding Cassette transporter family, 
inc1uding sorne cholesterol carriers such as ABCAI and ABCG5/G8 act as efflux 
pumps facilitating cholesterol export out of absorptive cells. 
In vitro studies undertaken to characterize intestinal lipid absorption have revealed 
relationships between glucose levels and lipid uptake. High extracellular glucose 
concentrations significantly increase brush border membrane fluidity and 
permeability at tight junctions in hum an intestinal mucosa (Komissarchik et al., 
1993; D'Souza et al., 2003b). Those studies demonstrated that glucose may affect 
the transepithelial transport of nutrients (D'Souza et al., 2003a; D'Souza et al., 
2003b). 
Furthermore, in vivo studies confirm the hypothesis that there may be a regulation of 
intestinallipid uptake by dietary glucose. An inverse relationship between glycemic 
load and HDL cholesterol was described (Liu et al., 2001; Slyper et al., 2005). It 
was reported that women who consume cholesterol with a low carbohydrate intake 
have lower concentrations of low density lipoproteiri (LDL) than those with a high 
carbohydrate intake (Lofgren et al., 2005). 
Increased cholesterol absorption has also been described in patients with diabetes 
mellitus. The prevalence of diabetes is increasing worldwide and coronary heart 
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disease (CHD) is the leading cause of death in type 2 diabetes mellitus (T2DM) (Gu 
et al., 1998). Patients with T2DM are two to three times more likely to die from 
CHD than non-diabetic individuals (Garcia et al., 1974; Stamler et al., 1993). 
Therefore, considerable attention has been focused on the dyslipidemia 
accompanying diabetes and metabolic syndrome. Exaggerated very-Iow density 
lipoprotein production In the liver represents a major pathway of the 
hypertriglyceridemia that characterizes the diabetic condition. On the other hand, a 
significant relationship exists between intestinally-derived triacylglycol (TG)-rich 
lipoproteins and the progression of atherosc1erosis (Gylling et al., 2004; Lally et al., 
2006). 
Although numerous investigations have attempted to elucidate the abnormal 
mechanisms of intestinal cholesterol absorption process in diabetic dyslipidemia, 
they have not given full consideration to nutrients other than TG and cholesterol. 
However, changing the carbohydrate content of a mixed me al altered the 
postprandial accumulation of chylomicrons (Harbis et al., 2001). Furthermore, high 
glucose levels alter the expression of various genes involved in high-density 
lipoprotein (HDL) metabolism (Tu and Albers, 2001). 
Accordingly, the main objective of this study was to evaluate the effect of glucose 
on the transport and metabolism of cholesterol in intestinal cells. The specific ai ms 
were to evaluate the effect of a high glucose level on i) cholesterol absorption 
processes; ii) the expression of proteins that may influence cholesterol uptake (SR-
BI, NPCIL1, CD36) and those favoring cholesterol export (ABCA1, ABCG5/G8); 
iii) enzymes that control cholesterol homeostasis; and iv) the status of 
transcriptional factors involved in cholesterol regulation. 
Establishing the relation between glucose levels and cholesterol transport and 
metabolism, may contribute to find new alternative therapeutic treatments 
improving the conditions of glucose and lipid related diseases such as obesity, 
coronary heart disease and diabetes mellitus among others. 
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ABSTRACT 
Growing evidence suggests that the small intestine may contribute to excessive 
postprandial lipemia, which is highly prevalent in insulin-resistant/type 2 diabetic 
individuals and substantially increases the risk of cardiovascular disease. The aim of 
the present study was to de termine the role of high glucose levels on intestinal 
cholesterol absorption, cholesterol transporter expression, enzymes controlling 
cholesterol homeostasis and the status of transcription factors. To this end, we 
employed highly differentiated and polarized cells (20 days of culture), plated on 
permeable polycarbonate filters. In the presence of [14C]-cholesterol, glucose at 25 
mM stimulated cholesterol uptake compared to Caco-2/15 cells supplemented with 
5 mM glucose (p<0.04). Because combination of 5 mM glucose with 20 mM of the 
structurally related mannitol or sorbitol did not change cholesterol uptake, we 
conc1ude that extracellular glucose concentration is uniquely involved in the 
regulation of intestinal cholesterol transport. The high concentration of glucose 
enhanced the prote in expression of the critical cholesterol transporter NPC ILl and 
that of CD36 (p<0.02) and concomitantly decreased SR-BI protein mass (p<0.02). 
No significant changes were observed in the protein expression of ABCAI and 
ABCG8, which act as efflux pumps favoring cholesterol export out of absorptive 
cells. At the same time, HMG-CoA reductase activity was decreased (p<0.007), 
whereas ACAT activity remained unchanged. FinalIy, increases were noted in the 
transcription factors LXRa, LXR~, PPAR~ and PPARy along with a drop in the 
protein expression of SREBP-2. Collectively, our data indicate that glucose at high 
concentrations may regulate intestinal cholesterol transport and metabolism in 
Caco-2/15 celIs, thus suggesting a potential influence on the cholesterol absorption 
process in type 2 diabetes. 
Key words: ABCAI, ABCG5/G8, SR-BI, CD36, NPCILI, PPAR, LXR, SREBP, 
ACAT and HMG-CoA reductase 
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INTRODUCTION 
Elevated plasma cholesterol levels constitute a major risk factor for atherosclerosis 
and coronary heart diseases (CHD) (60). Whole body cholesterol balance is 
regulated by the net effects of dietary cholesterol absorption, de novo cholesterol 
biosynthesis and biliary excretion from the liver (21, 49). A vailable evidence 
supports the concept that several proteins are involved in mediating intestinal 
cholesterol transport. While vanous transporters, including fatty acid 
translocase/cluster determinant 36 (FAT/CD36), scavenger receptor class B type l 
(SR-BI) and Niemann Pick CI-Likel (NPCIL1) may influence cholesterol uptake, 
the ATP Binding Cassette transporter family, including several cholesterol carriers 
(ABCA1, ABCB1, ABCG5/G8), act as efflux pumps favouring cholesterol export 
out of absorptive ceUs into the lumen or basolateral compartment. Among aU the 
cholesterol transporters, the enriched NPCILI protein in the apical membrane of 
polarized cells is considered essential for intestinal cholesterol absorption. To 
provide only a few examples, (i) mice deficient in NPCILI lack the ability to 
absorb cholesterol and exhibit prevailing protection against the rise in plasma and 
hepatic cholesterol associated with feeding mice high cholesterol diets (5, 22, 23); 
(ii) genetic modifications of NPCILI in cultured intestinal cells alter cholesterol 
uptake (73, 88, 90); and (iii) variations in NPClLl were found associated with 
reduced sterol absorption, low-density lipoprotein-cholesterol (LDL-C) levels (17) 
and LDL-C response to ezetimibe therapy (41, 75, 84). Although, various aspects of 
NPC 1 LI, as a cell surface transporter or an intracellular cholesterol transport prote in 
needs clarification (43), intensive research is focused on drugs that interact with 
NPClLl given their potential to treat individu aIs with hypercholesterolemia and to 
reduce their risk of developing CHD. 
The prevalence of diabetes is increasing worldwide and CHD is the leading cause of 
death in type 2 diabetes mellitus (T2DM) (35). Patients with T2DM are two to three 
times more likely to die from CHD than non-diabetic individuals (31, 77). 
Therefore, considerable attention has been focused on the dyslipidemia 
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accompanying diabetes and metabolic syndrome. Elevated li ver very-Iow density 
lipoprotein production represents a major pathway of the hypertriglyceridemia that 
characterizes the diabetic condition. On the other hand, a significant relationship has 
been shown between intestinally-derived triacylglycol (TG)-rich lipoproteins and 
the progression of atherosc1erosis. Increased cholesterol absorption has also been 
described in patients with T2DM (36, 52). Although numerous investigations have 
attempted to elucidate the abnormal mechanisms of intestinal cholesterol absorption 
process in diabetic dyslipidemia, they have not given full consideration of nutrients 
other than TG and cholesterol. However, it has been reported that changing the 
carbohydrate conteJ;).t of a mixed meal altered the postprandial accumulation of 
chylomicrons (37). Furthermore, a high glucose level alters the genetic expression 
ofvarious genes involved in high-density lipoprotein (HDL) metabolism in HepG2 
cells, inc1uding human ABCAl, SR-BI and hepatic lipase (79). The aims of the 
present study were 1) to evaluate the effect of a high glucose concentration on 
cholesterol absorption and 2) to explore the influence of an elevated glucose level 
on the expression of genes regulating cholesterol synthe sis and absorption in a cell 
culture system. 
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MATERIALS AND METHODS 
Cell culture 
The Caco-2115 cellline was obtained from Dr. JF Beaulieu (Department of Cellular 
Biology, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, 
Canada). This clone of the parent Caco-2 cellline (RTB37; American Type Culture 
Collection, Manassas, VA) has been extensively characterized (3, 6, 80) and was 
originally selected for expressing the highest level of sucrase-isomaltase among 
16 clones obtained by random cloning. Caco-2/15 cells were grown at 37°C with 5% 
COz in Dulbecco's Modified Eagle Medium (DMEM) (GIBCO-BRL, Grand Island, 
NY) containing 1% penicillin-streptomycin and 1% Glutamax (GIBCO-BRL) and 
supplemented with 10% decomplemented fetal bovine serum (FBS) (Flow, McLean, 
VA). Caco-2115 cells (passages 40-60) were maintained in T-75-cmz flasks 
(Coming Glass Works, Coming, NY). Cultures were split (1 :6) when they reached 
70-90% confluence, by use of 0.05% trypsin-0.5 mM EDTA (GIBCO-BRL). For 
individual experiments, cells were plated at a density of 1 x 106 cells/well on 24.5-
mm polycarbonate Transwell filter inserts with O.4-llm pores (Costar, Cambridge, 
MA), in DMEM (as described above) supplemented with 5% FBS. The inserts were 
placed into six-well culture plates, permitting separate access to the upper and lower 
compartments of the monolayers. Cells were cultured for various periods, including 
21 days, at which the Caco-2 cells are highly differentiated and appropriate for lipid 
metabolism (34, 54, 55, 61, 73). The medium was refreshed every second day. At 
day 21, Caco-2/15 cells were washed twice with phosphate buffered saline (PBS) 
(Invitrogen) and incubated in a serum-free supplemented DMEM (Invitrogen) (5 
mM or 25 mM glucose), added to the apical compartment, for 24 h. 
Cholesterol absorption by Caco-2/15 cells 
To study cholesterol uptake by the cells, a solution containing 0.113 /lCi [14C]_ 
cholesterol and 100 /lM cholesterol bound to albumin was prepared. The 
differentiated cells were incubated at 37°C for 30 min and 4 h in DMEM containing 
5 or 25 mM glucose, as well as cholesterol solution. At the end of the treatment, 
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cells were washed twice with PBS, scrapped in 1 mllysis buffer (5mM Tris, 15 mM 
NaCl, EDTA 5 mM, 0.1 % SDS, 1 % Triton X 100,0.5% sodium deoxycholate) and 
homogenized by sonication followed by a 5-min at 13800 g centrifugation to 
remove cell debris. An aliquot of 0.1 ml was placed in a scintillation vial with 
Ready Safe counting fluid (Beckman, Fullerton, CA). Radioactivity was measured 
by scintillation counting (LS 5000 TD, Beckman). Cell prote in was quantified by 
the Bradford method (BioRad). 
Acyl-Coenzyme A: cholesterol acyltransferase (ACAT) activity assay 
The activity of ACAT was determined at initial rates by adding 5 nmol of [14C]_ 
oleoyl-CoA (specific activity .... 167 Bq/nmol) to the mixture containing 190 ~g of 
cellular prote in to initiate the reaction in a buffer solution (pH 7.5) consisting of 
cholesterol, 0.04 M KH2P04, 50 mM NaF, 0.25 M sucrose, and 1 mM EDTA (73). 
After incubation for 10 min at 37°C, the reaction was stopped by adding 
ch10roform-methano1 (2: 1, v/v) followed by free cholesterol (FC) and cho1estery1 
ester (CE) as carriers. The FC and CE formed were isolated by TLC and counted. 
HMG-CoA reductase activity assay 
Enzymatic activity was assayed as described previously (19, 73). The reaction 
mixture contained 100 mM potassium phosphate (pH 7.4), 200 ~g of cellular 
protein, 20 mM glucose-6-phosphate, 12.5 mM dithiothreitol, 2.5 M NADP, and 1.2 
units of glucose-6-phosphate dehydrogenase. Initiation of the reaction was done by 
the addition of [14C]-HMG-CoA (200 Bq/nmol) for 30 min at 37°C. The e4C]-
mevalonate formed was converted into lactone by the addition of 10 N HCI, isolated 
by TLC, and counted using an internaI standard to correct for incomplete recovery. 
Western Blot 
To assess the presence ofNPClLl, SR-BI, CD36, ABCA1, ABCG8, ACAT, and 
HMG-CoA reductase, Caco-2115 cells were homogenized and prepared for Western 
blotting as described previously (56). The Bradford assay (Bio-Rad) was used to 
determine protein concentration. Proteins were denatured in sample buffer 
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containing SDS and p-mercaptoethanol, separated on a 7.5% SDS-PAGE gel, and 
blotted onto nitrocellulose membranes. Nonspecific binding sites of the membranes 
were blocked using 5% defatted milk proteins. Reactions took place by the addition 
of primary antibodies directed against targeted proteins. Reaction was revealed with 
species-specific horseradish peroxidase-conjugated secondary antibody. p-actin was 
used as an internaI control to confirm equalloading protein on SDS-PAGE. Blots 
were developed and proteins were quantified using a Hewlett-Packard scanner 
equipped with a transparency adaptor and UN-SCAN-IT (Silk Scientific 
Corporation) software. 
Immunocytochemical analysis 
Caco-2115 cells grown for 21 days and exposed to either low (5 mM) or high (25 
mM) glucose medium were fixed with 1 % glutaraldehyde in 0,1 M phosphate buffer 
for 2 hours and processed for embedding in Lowicryl at -30°C as described in 
details previously (7, 55, 58, 76). Thin sections were mounted on Parlodion-carbon 
coated grids and processed for the immunogold labeling. Various proteins were 
studied, name1y SR-BI, NPCILl, ABCAl, ABCG8 and CD36. The thin sections of 
the cells were first treated with a saturated solution of sodium metaperiodate for 10 
min, followed by 1 % ovalbumin and then incubated overnight at 4°C with the 
corresponding antibody. Grids were thoroughly rinsed with PBS and incubated with 
the prote in A-gold or an anti-rabbit IgG-gold complex for 30 min at room 
temperature. Upon counterstaining with uranyl acetate, the sections were examined 
with a Philips 410 electron microscope. The antibodies were used at the following 
dilutions NPCILI at 1:10; SRBI at 1:50; CD36 at 1:10; ABCAI at 1:10 and 
ABCG8 at 1: 10. In order to assess specificity on the labeling, control experiments 
were performed omitting the incubation with the primary antibody. Grids were only 
exposed to the prote in A-gold or the anti-rabbit IgG-gold complex for 30 minutes. 
For morphometrical evaluations, a large number of photographs were recorded at 
the original magnification of x14000; they were scanned and printed to the final 
magnification of x28000. The specific membrane domain was se1ected for 
morphometrical evaluation according to the specific localization of the transporters, 
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1.e. the apical membrane with its large number of microvilli or the basolateral 
membrane with its deep invaginations. First, the length of the membrane was 
measured and then the number of gold particles delineating the same membranes 
was counted. Results are expressed in number of gold particles per /lm (mean 
values ± SD). An image processing system (Videoplan 2, Carl Zeiss Inc. Toronto) 
was used. For each of the experiments and for each prote in studied, the length of 
apical membrane evaluated was in the range of ~800 /lm, while that of the 
basolateral membrane was in the range of ~250 /lm. The major difference in 
membrane length evaluated between apical and basolateral membranes is due to the 
presence of the large number of microvilli in the apical membrane. Morphometrical 
evaluations were also performed on the control experiments. 
RNA isolation 
Total RNA was isolated from Caco-2115 cells using the TRIzol reagent according to 
the manufacturer's instructions (Sigma Chemical Co.). Concentrations of RNA were 
determined by spectrophotometer analysis and the integrity of total RNA was 
assessed by electrophoresis. 
RT-PCR 
PCR experiments for transcription factors (LXRs, RXRs, PPARs, SREBP-2) genes, 
ACAT, and HMG-CoA reductase, as well as GAPDH (as a control gene) were 
performed using the mastercycler gradient (EPPENDORF®). Specific primers were 
designed to bind to regions with minimal homology, to span at least 1 intron for 
distinction from genomic DNA and to avoid nonspecific annealing (Table 1). All 
primers were Blast searched to confirm specificity for each individual isoform. 
Approximately 30-40 cycles of amplification were used at 95°C for 30 s,53-62°C 
for 30 s, and 72°C for 30 s. Amplicons were visualized on standard ethidium 
bromide-stained agarose gels. For all RT -PCRs, analysis of rnRNA expression was 
carried out during the exponential phase of the amplification, which was assessed in 
preliminary experiments for each pair of primers. 
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Statistical analysis 
Unless otherwise stated, aH values are given as mean values ± SD. Data were 
assessed by Student's two-tailed t-test. A p value <0.05 was considered statistically 
significant. 
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RESULTS 
Cholesterol absorption 
Following pre-incubation (24 h) of Caco-2115 cells with medium containing 5 or 25 
mM glucose, cholesterol uptake was determined at short-and long-term incubation 
times. As illustrated by Figure l, cells exposed to 25 mM glucose displayed a 
higher capacity to incorporate cholesterol compared with cells treated with 5 mM 
glucose (p<0.04). Furthermore, compared to control cells, the output of cholesterol 
at 6 h (23%, p<0.04) was also augmented at the long term incubation time (data not 
shown). 
To determine whether the influence of glucose on cholesterol transport could 
possibly be explained by the difference in the osmolarity of the 5 and 25 mM 
glucose solutions, we incubated Caco-2115 cells with mannitol and sorbitol 
combined to 5 mM glucose. The cholesterol uptake of cell monolayers maintained 
in 5 mM glucose plus 20 mM mannitol or sorbitol did not differ from cells 
maintained in physiological glucose (5 mM) media (Figure 2). We, therefore, 
conc1ude that extracellular glucose concentration is uniquely involved in the 
regulation of intestinal cholesterol transport. 
Protein expression of cholesterol transporters assessed by Western blot 
The enhanced cholesterol uptake exhibited by Caco-2/15 cells incubated with the 
high concentration (25 mM) of glucose may be due to differences in the expression 
of cholesterol transporters. To test this hypothesis, the prote in expression of 
cholesterol transporters present in intestinal epithelial cells was examined. We 
assessed NPCILI, CD36 and SR-BI that transport cholesterol into the enterocyte, 
as well as ABCA 1 and ABCG8 that are presumed to be involved in cholesterol 
efflux from the enterocyte toward plasma HDL or back into the intestinal lumen, 
respectively. Exposure to 25 mM glucose as compared to 5 mM glucose resulted in 
a significant increase in the protein expression ofNPCILI and CD36 along with a 
decrease in the prote in expression of SR-BI (Figure 3). On the other hand, the 
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prote in expression of both ABCA 1 and ABCG8 was not affected by the different 
glucose concentrations (Figure 4). 
Protein levels of cholesterol transporters assessed by high-resolution quantitative 
immunogold approach. 
Since Western blotting measures the total prote in mass without being able to 
distinguish the cellular localization of cholesterol transporters, we employed the 
Prote in A-gold immunocytochemical technique, to determine whether alterations in 
cholesterol transporters, as a function of glucose concentrations, were associated 
with their specific membrane domain. Electron microscopic immunocytochemical 
experiments mostly confirmed the findings obtained by Western blot. They revealed 
significant increases in immunogold labellings for NPCILI and CD36 in the 
luminal region of enterocytes, particularly associated with the apical plasma 
membrane lined by the microvilli (Figure 5). A representative illustration 
documents the immunochemical detection of CD36 in Caco-2/15 cells following 
exposure to different glucose levels (panel A: 5mM and panel B: 25 mM) (Figure 
6). However, the labelling of ABCAI by gold partic1es was decreased in the 
basolateral membrane following the addition of 25 mM glucose (Figure 5). 
Furthermore, no significant alterations were noted in the intensity of labelling of 
SR-BI and ABCG8 in the apical membrane (Figure 5). Importantly, under control 
conditions, the labeling was negligible and the few go Id partic1es present over the 
cells were rather randomly distributed. 
Involvement of NPC1Ll in cholesterol uptake 
In order to elucidate the specific contribution of NPCILI to cholesterol uptake in 
the presence of glucose, we employed ezetimibe, a selective hypocholesterolemic 
drug, which has been reported to bind NPCILI and substantially block cholesterol 
absorption. We could observe a lessened action of glucose when ezetimibe was 
added to the culture medium (Figure 7), highlighting the input ofNPCILI. 
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Regulatory enzymes of cholesterol metabolism 
Next, we detennined the impact of glucose on the regulatory sterol enzymes: HMG-
CoA reductase (EC 1.1.1.34), the rate-limiting step in cholesterol synthesis, and 
ACAT (EC 2.3.1.26), an integral prote in present in the rough endoplasmic reticulum 
(ER) that catalyzes the fonnation of CE from FC and fatty acyl-CoA. HMG-CoA 
reductase mRNA and prote in expression remained unchanged following increase of 
glucose to 25 mM glucose to Caco-2/15 cells (Figure 8). On the other hand, the 
higher glucose concentration led to a significant reduction in the enzymatic activity 
of HMG-CoA reductase (Figure 8). As to ACAT, no significant changes were 
recorded in the gene expression and activity after the exposure to 25 mM glucose 
(Figure 9). 
Transcription factors 
To approach the mechanisms triggered by glucose, we assessed the gene expression 
of several factors that affect the transcription of a variety of genes associated with 
lipid and cholesterol metabolism, inc1uding liver X receptors (LXRa, 13), 
peroxisome proliferator-activated receptors (PPARa, 13, y), retinoid X receptors 
(RXRa, 13), and protein and gene expression of sterol regulatory element binding 
protein-2 (SREBP-2). Data on Figures 10 to 12 illustrate how glucose at the high 
concentration of 25 mM impacted on the expression of the different nuc1ear and 
transcription factors in Caco-2/15 cells. It did not cause any significant variation on 
the mRNA levels of RXRa (Figure 10C), RXRj3 (Figure lOD), PP ARa (Figure 
lIA), and SREBP-2 (Figure 12A) gene expression, whereas it produced a 
significant enhancement in gene expression of LXRa (Figure 1 DA) and LXRj3 
(Figure lOB), as well as PPARj3 (Figure lIB) and PPARy (Figure IlC). Finally, 
when we explored the effect of glucose on SREBP-2 protein expression, we 
detected a significant reduction upon exp 0 sure to 25 mM glucose (Figure 12B). 
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DISCUSSION 
Numerous studies have dealt with the regulation oOntestinal fat absorption by lipid 
components (27, 57, 61, 70). However, the role of carbohydrates has bare1y been 
investigated. In the present paper, we showed that high glucose concentrations (i) 
enhance cholesterol tranSport in Caco-2/15 cells by upregulating the prote in 
expression of NPCILI and CD36; and (ii) reduce SR-BI prote in mass and HMG-
CoA reductase activity without altering ABCAI and ABCG8, involved in 
cholesterol efflux. A schematic diagram (Figure 13) depicts the major players in 
cholesterol transport and metabolism. Moreover, our studies document that 
particular transcription factors are glucose sensors, which may explain the impact of 
glucose on cholesterol absorption via its action on specific cholesterol transporters. 
In the present study, we have found a relationship between glucose and cholesterol 
assimilation. In order to clarify whether this observation could be explained by 
differences in the osmolarity of the 5 and 25 mM glucose solutions, we incubated 
Caco-2115 cells with 20 mM mannitol or sorbitol combined to 5 mM glucose. Our 
results indicate that the exposure of Caco-2/15 cells to high concentrations of 
glucose, but not to stiucturally re1ated compounds such as mannitol and sorbitol, 
increased cholesterol transport capacity. 
NPCILI is a critical protein for cholesterol absorption by the small intestine, since 
NPCILI knockout mice exhibited a reduction in intestinal cholesterol absorption and 
are insensitive to ezetimibe (5,23), a drug that lowers serum cholesterol by reducing 
cholesterol absorption. In addition, the use of genetically-modified intestinal 
epithelial cells and ezetimibe support the central role for NPCILI in intestinal 
cholesterol absorption (28, 31, 73, 90). The high glucose level used in our 
investigation raised not only cholesterol uptake but also the protein expression of 
NPCILI. Our results are in line with the findings in diabetic patients who displayed 
increased levels of NPCILI rnRNA in intestinal tissue (52). Increased cholesterol 
absorption has also been shown in streptozotocin diabetic rats (89), in which 
NPCILI mRNA was found to be increased (51). Altogether, these fmdings suggest 
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an important role for intestinal NPC 1 L 1 in the delivery of cholesterol to the blood 
circulation in the presence of high glucose levels. However, additional studies are 
needed to examine whether glucose may influence the absorption of cholesterol via 
non-mediated passive uptake of cholesterol or other intestinal transporters since 
residual cholesterol absorption persisted in NPCILI-deficient mice (5). 
In the present investigation, ,the prote in CD36 was highly expressed in intestinal 
luminal surface of enterocytes (82) and was found to be raised upon exposure to 
high glucose levels. Undoubtedly, CD36 does contribute to the intestinal transport 
of cholesterol since enterocytes isolated from Cd3ù/- mice exhibit reduced uptake 
of cholesterol (60%) (68). From the present experiments, we can deduce that 
elevated glucose-mediated cholesterol uptake is likely related to the up-regulation of 
NPCILI and CD36. Interestingly, the participation of NPCILI and CD36 was 
reinforced by the experiments with ezetimibe, although the former displayed more 
sensitivity to ezetimibe inhibition (32) than the latter (82). Of note is the mode st 
decrease in cholesterol uptake from the apical side, in line with the studies of Field 
et al. (23) probably because the glucuronidated form of ezetimibe is more potent 
than the native unmodified drug in inhibiting cholesterol absorption by binding more 
avidly to enterocyte brush-border membranes (83). 
SR-BI was originally identified as a novel scavenger receptor that mediates 
endocytosis of acetylated LDL (2). Subsequent studies revealed that SR-BI is a cell 
surface receptor that binds HDL with high affinity and mediates the selective uptake 
by liver and steroidogenic tissues of cholesterol esters without endocytic uptake of 
HDL apolipoproteins (1). Efflux of radiolabeled cholesterol on the cell surface to 
HDL partic1es is also promoted by SR-BI (45). Together, SR-BI accelerates reverse 
cholesterol transport by promoting cholesterol efflux from peripheral cells, 
inc1uding macrophages in vascular walls (16), and selective uptake of HDL-C by 
hepatocytes for excretion of cholesterol as bile acids. Therefore, SR-BI plays crucial 
roles in the atheroprotective functions of HDL (48). Additional investigations have 
reported that SR-BI is highly expressed in the luminal side of proximal small 
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intestine villi where the bulk of cholesterol absorption takes place and may be 
responsible for the cholesterol uptake by enterocytes (4, 39, 55). Nevertheless, the 
involvement of SR-BI in cholesterol absorption has been questioned since variable 
results were obtained with genetically-modified mice (8, 62). In the present 
investigation, glucose in high concentrations downregulates SR-BI prote in 
expression. This suppressive effect has also been reported in hepatocytes HepG2 
cells following exposure to high glucose concentrations (67). The use of inhibitors 
for select signal transduction pathways in HepG2 cells indicated that glucose 
suppression of SR-BI expression is partially mediated by the activation of the p38 
MAPK-Spl pathway (67). Further studies are needed to determine the detailed 
regulatory mechanisms of intestinal SR-BI expression. 
We reasonably hypothesized that increased NPCILl- and CD36-mediated 
cholesterol uptake would lead to reduced HMG-CoA reductase activity. Based on 
the data in Figure 8, this assumption tumed out to be true. However, ACAT was 
insensitive to the accumulation of intracellular cholesterol, probably because the 
latter did not exp and the fini te cholesterol substrate pool for ACAT and manifested 
a high-order dependence on ER cholesterol concentration (11, 14). 
The coordinated regulation of genes implicated in cholesterol homeostasis is 
govemed by the actions of several transcription factors, such as LXRs and pp ARs. 
AIso, SREBPs are transcription factors and crucial regulators of cholesterol 
synthesis and metabolism. In response to specifie effectors, LXRs form 
heterodimers with RXRs that regulate an integrated network of genes that control 
whole body cholesterol and lipid homeostasis assays (44, 53). In particular, LXR 
appears to serve as a safety valve to limit free cholesterol in tissues that are 
experiencing high cholesterol flux (20). Moreover, glucose activates LXR at 
physiological concentrations expected in the liver and induces expression of LXR 
target genes with efficacy similar to that of oxysterols, the known LXR ligands (66). 
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Therefore, since these nuclear factors act as glucose sensors (66) and exhibit anti-
diabetic effects (13, 50), we first measured their gene expression. LX~a and LXR~ 
mRNA were increased by the presence of 25 mM glucose in Caco-2/15 cells, but 
were not accompanied with the expected induction of ABCAI and ABCG8 protein 
expression. This may be due to the irresponsiveness of RXRs that work as partners 
withLXRs. 
The family of SREBP regulates the coordinated expression of genes involved in 
lipid synthesis and uptake (10). Three SREBP isoforms are known in mammals, 
SREBP-Ia, SREBP-lc and SREBP-2. While SREBP-Ic preferentially activates 
genes required for fatty acid (FA) synthesis and their incorporation into TGs and 
phospholipids, SREBP-2 preferentially activates the LDL- receptor gene and 
vanous genes required for cholesterol synthesis such as HMG-CoA reductase 
(EC1.1.1.34) (42). SREBP-la is an activator of both, the cholesterol and FA 
biosynthetic pathway, but it is present in much lower amounts (74). Since SREBP-2 
plays a more important role in the regulation of cholesterol synthesis in the intestine 
(25, 26), we measured the gene and protein expression of SREBP-2. Our results 
highlighted a decline in the prote in expression ofSREBP-2 without any alteration of 
SREBP-2 mRNA. Similarly, the gene and prote in expression of HMG-CoA 
reductase were not changed, but the activity was decreased, suggesting post-
transcriptional mechanisms for SREBP-2 and HMG-CoA reductase. 
pp ARs have been shown to regulate the expression of genes involved in a variety of 
biological processes, including lipid metabolism and insulin sensitivity (18, 81). 
PP ARa regulates numerous aspects of FA catabolism, whereas pp AR)' controls 
adipocyte differentiation, systemic glucose levels and lipid homeostasis (65, 87). 
PPAR& is also involved in development, lipid metabolism, and epidermal cell 
proliferation (59). The PPARs are ligand-dependent transcription factors that 
regulate target genes expression by binding to characteristic DNA sequences termed 
peroxisome proliferators response element (PPREs) located in the 5' -flanking 
region of target genes (33, 69). Each receptor binds to its PPRE as a heterodimer 
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with the receptor for 9-cis retinoic acid, the RXR. Upon binding a ligand, the 
conformation of a pp AR is altered and stabilized so that a binding cleft is created, 
and recruitment of transcriptional coactivators occurs. In the present study, 
treatment of Caco-2115 cells with 25 mM glucose enhanced the gene expression of 
PPARp and PPARy and concomitantly decreased the protein concentration of 
SREBP-2. Similarly, PPARy activation by troglitazone downregulated cholesterol 
synthesis in Caco-2 cells by a reduced concentration of SREBP-2 prote in (47). 
Glucose absorption in the small intestine is mediated by the combined action of two 
glucose transporters in the enterocytes: the sodium-dependent D-glucose co 
transporter SGLTI in the brush-border membrane and the sodium-independent 
glucose transporter GLUT2 in the basolateral membrane (40, 46). Dietary glucose 
significantly influences blood glucose concentration (63), as well as glucose and fat 
metabolism in the liver (15, 78). Apparently mammals deve10ped a highly complex 
regulatory network in which small intestinal sugar absorption steers the regulation of 
gastric and intestinal mobility (30, 71, 72), liver metabolism (9, 29) and insulin 
secretion (64, 86). Both, the glucose concentration in the small intestinal lumen and 
the activity of glucose uptake systems SGLTI and GLUT2, determine the D-glucose 
concentration in the small intestinal submucosa and the portal blood. In the present 
study, glucose was effective in regulating cholesterol uptake and intracellular 
processing. Since the excessive consumption of diets containing high levels of 
carbohydrates enhances the absorption of monosaccharides and influences the risk 
of developing insulin resistance and T2DM (24), we reasonably propose that 
glucose-mediated intestinal cholesterol may contribute to increasing circulating 
cholesterol and, consequently, the risk of developing CHD, a feature ofT2DM. 
In conclusion, our experiments provide evidence that the process of intestinal 
cholesterol uptake is regulated by glucose concentrations, which modify important 
cholesterol transporters and transcription factors. In fact, high glucose 
concentrations may presumably modify the transcription factors, which in tum 
altered the cholesterol transporters, and therefore cholesterol uptake. 
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TABLE 1. Sequences of the specifie primers, as confirmed by BLAST sequence 
analysis, designed to amplify human HMG-CoA reductase, ACAT-2, LXRs, 
pp ARs, RXRs and SREBP-2 isoforms by RT -PCR. 
Isofonn Direction 5'-3' Primer sequence Product Reference 
size (bp) 
hHMGCoA-R forward ACC CTT AGT GGC TGA AAC AGA TAC CC 291 designed 
reverse AAC TGT CGG CGA AT A GAT ACA CCA CG 
hACAT-2 forward CTC TAC TTC CTC TTC TGC CC 128 designed 
reverse GAT GAA GCA GGC ATA GAG CA 
hLXRa forward GCT GCA AGT GGA ATT CAT CAA CC 166 (12) 
reverse ATA TGT GTG CTG CAG CCT CTC CA 
hLXR~ forward GGA GCT GGC CAT CAT CTC A 132 designed 
reverse GTC TCT AGC AGC ATG ATC TCG ATA GT 
hPPARa forward CCA GGC TTC GCA AAC TT 591 designed 
reverse CCC GTC TCC TTT GTA GTG CT 
hPPAR~ forward GCT TTG TCA CCC GTG AGT T 354 designed 
reverse AGG TCT CGG TTT CGG TCT TC 
hPPARy forward AGA CAA CAG ACA AAT CAC CAT 400 (91) 
reverse CTT CAC AGC AAA CTC AAA CTT 
hRXRa forward ATA AGC ATC ACA TTT TGG GG 417 (85) 
reverse GAC ATG CAG ATG GAC AAG T 
hRXR~ forward ATT AAC TCA ACA GTG TCA CTC CC 503 (85) 
reverse TT A GTC ACA GGG TCA TTT GG 
hSREBP-2 forward ATG GTG TGA TTG TCC TGA GCG TCT 341 designed 
reverse TTC GTC TTC AAA GCC TGC CTC AGT 
hGAPDH forward GTC CAC TGG CGT GTT CAC CA 260 (38) 
reverse GTG GCA GTG ATG GCA TGG AC 
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FIGURE LEGENDS 
Figure 1 
Figure 2 
Figure 3 
Figure 4 
Effect of glucose concentrations on cholesterol uptake in Caco-2/15 
cells. Differentiated Caco 2/15 cells were cultured for 24 h in 
medium DMEM containing 5 or 25 mM glucose. At the end of this 
pre-incubation, cells were exposed to 100 IlM cholesterol containing 
250000 DPM [14C]-cholesterol in the presence of the same 
concentrations of glucose for 30 min. Results are expressed as 
nmoVmg cen protein. Mean values ± SD. n=4. *p<0.04 versus 5 mM 
glucose condition. 
Combinatory effect of glucose and· mannitol or sorbitol on 
cholesterol uptake in Caco-2/15 cens. Differentiated Caco 2/15 cens 
were cu1tured for 24 h in medium DMEM containing 5 mM, 5 mM 
glucose + 20 mM mannitol, 5 mM glucose + 20 mM sorbitol, or 25 
mM glucose. At the end of this pre-incubation, cens were exposed to 
100 J..lM cholesterol containing 250000 DPM [14C]-cholesterol in the 
presence of the same concentrations of sugars for 30 min. Results 
are expressed as nmoVmg cell protein. Mean values ± SD. n=4. 
*p<0.04 versus 5 mM glucose condition. 
Effect of glucose concentrations on the prote in expreSSIOn of 
transporters mediating cholesterol influx. Caco 2/15 cens were 
cultured for 24 h in DMEM containing 5 or 25 mM glucose. Western 
blot was used to analyze the prote in expression of NPCILI (A), 
CD36 (B) and SR-BI (C). Mean values ± SD. n=4. *p<0.02 versus 5 
mM glucose condition. 
Effect of glucose concentrations on the protein expreSSIOn of 
transporters mediating cholesterol efflux. Caco 2/15 cens were 
cultured for 24 h in DMEM containing 5 or 25 mM glucose. Western 
blot was used to analyze the prote in expression of AB CA 1 (A) and 
ABCG8 (B). Mean values± SD. n=4. 
Figure 5 
Figure 6 
Figure 7 
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Immunocytochemical evaluation of cholesterol transporters 
following incubation of Caco 2/15 cells were cultured for 24 h in 
DMEM containing 5 or 25mM. Thereafter, cells were fixed with 1 % 
glutaraldehyde and embedded in Lowicryl. Immunogold labelings 
were carried out on thin sections. Immunogold labeling for NPC1L1 
(A), CD36 (B), SR-BI (C), ABCA1 (D) and ABCG8 (E) were 
quantified. For each of the proteins, the tota11ength of apical and 
basolateral membranes evaluated was in the range of 800 !lm and 250 
!lm, respectively. Under control conditions, the labe1ing was 
negligible with few go Id particles randomly distributed over the cells. 
For the 5 and 25 mM glucose experiments, the control prote in A-gold 
density (go Id particles/!lm) on apical membrane was 0.037± 0.006 
and 0.023 ± 0.012, respectively, and on basolateral region: 0.076 ± 
0.048 and 0.063 ± 0.012, respectively. For the control IgG gold, the 
density (gold particles/!lm) on the apical membrane was 0.021 ± 
0.005 and 0.015 ± 0.007 for 5 and 25 mM glucose, respectively, and 
on basolateral membrane 0.037 ± 0.018 and 0.050 ± 0.015, 
respectively. Mean values ± SEM. *p<0.05 
CD36 detection in Caco-2/15 cells as a representative illustration of 
the immunocytochemical detection. Prote in A-gold 
immunocytochemical technique was applied with the specific 
polyclonal antibody directed against CD36 to reveal it in the apical 
membrane. Panel A represents Caco-2/15 cells cultured with 5 mM 
glucose, whereas Panel B corresponds to Caco-2/15 cells cultured 
with 25 mM glucose. MV, microvilli. Bars= 0.5!lm. 
Interference of Ezetimibe with the uptake of cholesterol III the 
presence of glucose. In order to delineate the role ofNPC1L1 in the 
increased glucose-mediated cholesterol absorption, ezetimibe (100 
!lM) was added to the medium of Caco-2/15 cells cultured at the 
experimental conditions described in the legend of Figure 3. Results 
Figure 8 
Figure 9 
Figure 10 
Figure 11 
Figure 12 
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are expressed as % of controls. Mean values ± SD. n=3. *p<O.05 
versus 5 mM glucose condition. 
Effect of glucose concentrations on HMG-CoA reductase gene 
expression, prote in mass and activity. Caco 2/15 cens were treated 
as described in the legend of Figure 3 and tested for transcript levels 
(A) and prote in mass (B) by RT-PCR and Western blotting, 
respectively. Cell homogenates were assayed for HMG-CoA 
reductase activity (C). Mean values ± SD. n=4. 
*p<O.007 versus 5 mM glucose condition. 
Effect of glucose concentrations on ACAT gene expressIOn and 
activity. Caco 2/15 cens were treated as described in the legend of 
Figure 3 and tested for transcript levels (A) by RT-PCR. cen 
homogenates were assayed for ACAT activity (B). Mean values ± 
SD. n=4. 
Effect of glucose concentrations on the gene expressIOn of the 
nuclear receptors LXR and RXR. Caco 2/15 cens were treated as 
described in the legend of Figure 3. The transcript levels of LXRa 
(A), LXR~ (B), RXRa (C) and RXR~ (D) were assessed by RT-
PCR. Representative autoradiograms of the different amplicons are 
shown. Mean ± SD. n=5. *p<O.004 and **p<O.001 versus 5 mM 
glucose condition. 
Effect of glucose concentrations on the gene expreSSIOn of the 
nuclear receptors pp AR. Caco 2/15 cells were treated as described in 
the legend of Figure 3. The transcripts of PP ARa (A), PPAR~ (B) 
and PPARy (C) were assessed by RT-PCR. Representative 
autoradiograms of the different ampli cons are shown. Mean ± SD. 
n=5. 
*p<O.003 and **p<O.002 versus 5 mM glucose condition. 
Effect of glucose concentrations on the gene and prote in expression 
of SREBP-2. Caco 2/15 cens were treated as described in the legend 
of Figure 3. The levels of transcripts (A) and protein expression (B) 
Figure 13 
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were determined by RT-PCR and Western blotting, respectively. 
Mean ± SD. n=5. *p<O.04 versus 5 mM glucose condition. 
Diagram of the main players influencing cholesterol transport III 
intestinal epithe1ial cells. Uptake of alimentary or biliary cholesterol 
is mediated by putative sterol transporters such as NPC 1 LI, SR-BI 
and FAT /CD36. Excessive cholesterol is secreted back to the 
intestinal lumen by the ABCG5/ ABCG8 heterodimer localized at the 
apical membrane of the enterocyte. Similarly, ABCAI promotes 
cholesterol efflux (through the basolateral membrane) to plasma 
apolipoprotein A-l, thereby enhancing the formation of nascent HDL. 
Key enzymes such as HMG-CoA reductase and AC AT contribute to 
cholesterol homeostasis by synthesizing and esterifying, respective1y, 
intracellular cholesterol. Most of the processes, involved in 
cholesterol metabolism, are controlled by transcription factors (RXR, 
LXR, SREBP-2 and PPAR. According to our data, glucose-mediated 
cholesterol uptake may be sensed by transcription factors, which in 
tum altered the cholesterol transporters and downregulated 
cholesterol biosynthesis. 
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Discussion 
Numerous studies have dealt with the regulation of intestinal fat absorption by lipid 
components. However, the role of carbohydrates has barely been investigated. In the 
present study, we showed that high glucose concentrations (i) enhanced cholesterol 
transport in Caco-2115 cells by upregulating the protein expression of NPCILI and 
CD36; and (ii) reduced SR-BI prote in expression and HMG-CoA reductase activity 
without altering ABCAI and ABCG8, involved in cholesterol efflux. Moreover, our 
studies documented that particular transcription factors are glucose sensors, which 
may explain the impact of glucose on cholesterol absorption via its action on 
specific cholesterol transporters. 
Intestinal cholesterol absorption is a multistep process that is regulated by multiple 
genes, and the absorption efficiency of cholesterol is most likely determined by the 
net effect between influx and efflux of intraluminal cholesterol molecules. 
NPCILI is an essential and a critical protein for cholesterol absorption by the small 
intestine, since NPCILI knockout mice exhibited a reduction in intestinal 
cholesterol absorption and are insensitive to ezetimibe (Altmann et al., 2002; Davis 
et al., 2004), a potent drug that lowers serum cholesterol by reducing cholesterol 
absorption. In addition, the use of genetically-modified intestinal epithelial cells and 
ezetimibe support the central role for NPCILI in intestinal cholesterol absorption 
(Garcia et al., 1974; Sane et al., 2006; Yu et al., 2006; Field et al., 2007). We found 
that the high glucose lev el employed in our investigation raises not only cholesterol 
uptake but also the expression ofNPCILl. Our results are in line with the findings 
in diabetic patients who displayed increased levels ofNPCILI rnRNA (Lally et al., 
2006). Increased cholesterol absorption has also been shown in streptozotocin 
diabetic rats (Young et al., 1988), in which NPCILI mRNA was found to be 
increased (Lally et al., 2007). Altogether, these findings indicate an important role 
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for intestinal NPC1L1 in the delivery of cholesterol to the blood circulation in the 
presence ofhigh glucose levels. 
CD36, a protein highly expressed on the luminal surface of enterocytes (van 
Bennekum et al., 2005) was found to increase following the administration of high 
glucose levels. Undoubtedly, CD36 must contribute to the intestinal transport of 
cholesterol since enterocytes isolated from the small intestines of cd3()/- mice, 
when compared with wild type counterparts, exhibited reduced uptake of cholesterol 
(60%) (Nassir et al., 2007). 
From the present experiments, we can deduce that the elevated glucose-mediated 
cholesterol uptake is likely related to the up-regulation of NPC1L1 and CD36. 
Interesting1y, the participation of NPC1L1 and CD36 was more reinforced by the 
experiments with ezetimibe, although the former displayed more sensitivity to 
ezetimibe inhibition (Garcia-Calvo et al., 2005) than the latter (van Bennekum et al., 
2005). Of note is the modest decrease in cholesterol uptake from the apical side, in 
line with the studies of Field et àl. (Field et al., 2001a) probably because the 
glucuronidated form of ezetimibe is more potent than the native unmodified drug in 
inhibiting cholesterol absorption by binding more avidly to enterocyte brush-border 
membranes (van Heek et al., 2000). 
SR-BI was originally identified as a novel scavenger receptor that mediates 
endocytosis of acetylated LDL (Acton et al., 1994). Subsequent studies revealed that 
SR-BI is a cell surface receptor that binds HDL with a high affinity and mediates 
the selective uptake by the liver and steroidogenic tissues of cholesterol esters 
without the endocytic uptake of HDL apolipoproteins (Acton et al., 1996). In 
addition, SR-BI may facilitate the initial steps of HDL-mediated cholesterol efflux 
in the arterial wall (Ji et al., 1997). Together, SR-BI accelerates reverse cholesterol 
transport by promoting cholesterol efflux from macrophages in vascular walls 
(Chinetti et al., 2000) and selective uptake of HDL-C by hepatocytes for excretion 
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of cholesterol as bile acids. Therefore, SR-BI plays crucial roles in atheroprotective 
functions ofHDL (Krieger, 2001). 
Additional studies, employing the high-resolution immunogold technique revealed 
that SR-BI may be responsible for the cholesterol uptake by enterocytes; they found 
SR-BI labeling mainly over microvilli of the enterocyte, where the bulk of 
cholesterol absorption takes place (Hauser et al., 1998; Altmann et al., 2002; Levy 
et al., 2004). Despite these results, the involvement of SR-BI in cholesterol 
absorption has been questioned since inconsistent results were obtained with 
genetically-modified mice (Mardones et al., 2001; Bietrix et al., 2006). 
In the present study, we showed that an increase in the concentration of glucose 
downregulates the prote in expression of SR-BI in Caco-2/15 cells. Such suppressive 
effect of glucose has also just been reported in hepatocytes HepG2 cells (Murao et 
al., 2008). The use of inhibitors for select signal transduction pathways in HepG2 
cells indicated that glucose suppression of SR-BI expression is partially mediated by 
the activation of the p38 MAPK-Sp1 pathway (Murao et al., 2008). Further studies 
are needed to determine the detailed regulatory mechanisms of intestinal SR-BI 
expressIon. 
Our hypothesis was that if NPC1L1 and CD36 mediate an increased cholesterol 
uptake, it is conceivable that the highly available cholesterol in Caco-2/1S cells 
would lead to reduced HMG-CoA reductase activity. Based on the data in Figure 7, 
this assumption turned out to be true. However, ACAT was insensitive to the 
accumulation of intracellular cholesterol, probably because the latter did not expand 
the limited cholesterol substrate pool for ACAT and manifested a high-order 
dependence on ER cholesterol concentration (Chang et al., 1997; Buhman et al., 
2000). 
The coordinated regulation of genes implicated in cholesterol homeostasis is 
govemed by the actions of several transcription factors, such as LXRs and pp ARs. 
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Also, SREBPs are transcription factors that are crucial regulators of cholesterol 
synthesis and metabolism. In response to specific effectors, LXRs form a 
heterodimer with the RXRs and regulate an integrated network of genes that control 
whole body cholesterol and lipid homeostasis assays (Lehmann et al., 1997; 
Janowski et al., 1999). 
In particular, LXR appears to serve as a safety valve to limit free cholesterol in 
tissues that are experiencing high cholesterol flux (Cummins and Mangelsdorf, 
2006). Since these nuclear factors act as glucose sensors (Mitro et al., 2007) and 
exhibit anti-diabetic effects (Cao et al., 2003; Laffitte et al., 2003), we first 
measured their gene expression. LXRa and LXR~ mRNA was increased by the 
presence of 25 mM glucose in Caco-2/l5 cells, but it was not accompanied with the 
expected induction of ABCAI and ABCG8 prote in expression. This may be due to 
the irresponsiveness of RXRs that work as partners with LXRs. 
The family of SREBP regulates the coordinated expression of genes involved in 
lipid synthesis and uptake (Brown and Goldstein, 1999). Three SREBP isoforms are 
known in mammals, SREBP-la, SREBP-lc and SREBP-2. While SREBP-Ic 
preferentially activates genes required for fatty acid (FA) synthesis and their 
incorporation into TGs and phospholipids, SREBP-2 preferentially activates the 
LDL- receptor gene and various genes required for cholesterol synthesis such as 
HMG-CoA reductase (ECl.l.1.34) (Horton et al., 2002). SREBP-la is an activator 
of both the cholesterol and FA biosynthetic pathways, but it is present in much 
Iower amounts (Shimomura et al., 1997). Since SREBP-2 plays a more important 
role in the regulation of cholesterol synthesis in the intestine (Field et al., 2001a, b), 
we therefore measured the gene and prote in expression of SREBP-2. Our results 
highlighted a decline in the prote in expression of SREBP-2 without any alteration of 
SREBP-2 mRNA. Similarly, the gene and prote in expression of HMG-CoA 
reductase were not changed, but its activity was decreased in a significant manner, 
suggesting post-transcriptional mechanisms for SREBP-2 and HMG-CoA reductase 
regulation. 
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pp ARs have been shown to regulate the expression of genes involved in a variety of 
biological processes, including lipid metabolism and insulin sensitivity (Vamecq 
and Latruffe, 1999; Corton et al., 2000). PPARu regulates numerous aspects of FA 
catabolism, whereas PPARy controls adipocyte differentiation, systemic glucose 
levels and lipid homeostasis (Michalik and Wahli, 1999; Willson et al., 2000). 
pp AR8 is also involved in deve1opment, lipid metabolism and epidermal cell 
proliferation (Lim et al., 1999). The pp ARs are ligand-dependent transcription 
factors that regulate target genes expression by binding to characteristic DNA 
sequences termed peroxisome proliferators response e1ement (PPREs) located in the 
5' -flanking region of target genes (Gearing et al., 1993; Palmer et al., 1995). Each 
receptor binds to its PPRE as a heterodimer with the receptor for 9-cis retinoic acid, 
the RXR. Upon binding a ligand, the conformation of a PP AR is altered and 
stabilized so that a binding cleft is created, and recruitment of transcriptional 
coactivators occurs. In the present study, treatment of Caco-2/15 cells with 25 mM 
glucose enhanced the gene expression of PPAR~ and PPARy and concomitantly 
decreased the protein concentration of SREBP-2. Similarly, PPAR activation by 
troglitazone downregulated cholesterol synthesis in Caco-2 cells by reducing the 
expression of SREBP-2 protein (Klopotek et al., 2006). 
All these data add new key e1ements to the complex relationship linking 
carbohydrate and cholesterol intestinal assimilation and metabolism. The complete 
mechanism involved in the glucose-induced regulation of uptake process is not yet 
fully identified and/or understood. An alteration of the physical properties of the 
enterocyte brush border, which in turn regulates the activity of membrane 
transporters, is probable, but other regulation pathways should also be considered. 
In conclusion, glucose at 25 mM stimulated cholesterol uptake by Caco-2 cells. The 
high concentration of glucose enhanced the protein expression of the critical 
cholesterol transporters NPCILI and CD36, and concomitantly decreased SR-BI 
protein expression. No significant alterations were observed in the prote in 
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expression of ABCAI and ABCG8, which act as efflux pumps favoring cholesterol 
export out of absorptive cells. At the same time, HMG-CoA reductase activity was 
significantly decreased, whereas ACAT activity remained unchanged. FinaIly, an 
increase was noted in the transcription factors LXRa, LXR~, PPAR~ and PPARy 
along with a drop in the protein expression of SREBP-2. 
Collectively, our experiments indicate that glucose at high concentrations may 
regulate intestinal cholesterol transport and metabolism in Caco-2 cells, modifying 
important cholesterol transporters and transcription factors, thus suggesting a 
potential influence on the cholesterol absorption process in type 2 diabetes. 
In our society, morbidity and mortality from cardiovascular diseases is becoming an 
increasingly severe problem. Overnutrition and a sedentary lifestyle lead to obesity 
and hypercholesterolemia already in a high percentage of children, who will be 
future patients with atherosclerosis-associated diseases (Ernst and Obarzanek, 1994; 
Gidding, 1999; Belay et al., 2004; Cruz and Goran, 2004). Certainly, preventive 
educational programs have to be developed to adjust and prevent this process. 
However, also therapeutic options have to be improved to ameli orate 
hypercholesterolemia. 
Clearly, intracellular handling of cholesterol needs more emphasis, as weIl as the 
regulation of cholesterol homeostasis during development. Evidently, the CUITent 
situation allows to identify promising targets for cholesterol-lowering therapies at a 
molecular level and to develop effective means to prevent cardiovascular disease in 
the future. 
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Annexe 
Reactives used: 
Company Dilution 
Antibodies 
SR-BI Novus 1/15000 
ê-actine Sigma 1/40000 
NPC1L1 Novus 1/500 
CD36 Santacruz 1/1000 
ABCA1 Novus 1/500 
ABCG8 Santacruz 1/500 
SREBP-2 Cayman 1/1000 
HMGCoA Upstate 1/1000 
Ezetimibe (Ezetrol) Schering-Plough 
